Search Result
Results for "
Humanized monoclonal antibody
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P9906
-
|
Anti-Human VEGF, Humanized antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
-
-
- HY-P9904
-
|
MPDL3280A; RG-7446; RO-5541267
|
PD-1/PD-L1
Apoptosis
Autophagy
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
-
-
- HY-P99859
-
|
LY3002813
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
|
-
-
- HY-P9906A
-
|
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
|
-
-
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized antibody; LDP-02; MLN-002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
-
- HY-P9912
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
-
- HY-P9910
-
|
GA101; Anti-Human CD20 type II, Humanized antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
-
-
- HY-P9981
-
|
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
-
-
- HY-P9914
-
|
Anti-Human C5, Humanized antibody; h5G1.1
|
Complement System
|
Cardiovascular Disease
Neurological Disease
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
|
-
-
- HY-P9952
-
|
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
|
-
-
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
|
-
-
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
-
- HY-P99372
-
|
Anti-NCAM1/ CD56 Reference antibody (lorvotuzumab)
|
ADC Antibody
|
Cancer
|
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
|
-
-
- HY-P99043
-
|
SC-0001
|
Notch
|
Cancer
|
|
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
|
-
-
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
-
- HY-P99854
-
|
RC48-0
|
EGFR
ADC Antibody
|
Cancer
|
|
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
|
-
-
- HY-P99329
-
|
Anti-Human CD33 Recombinant antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
|
-
-
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
-
-
- HY-P9945
-
|
SB 240563
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
-
- HY-P99509
-
-
-
- HY-171135
-
-
-
- HY-P99153
-
|
MORAb-003
|
Antibiotic
|
Cancer
|
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
|
-
-
- HY-P9945A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
-
- HY-P99379
-
|
CAN04; Anti-IL-1RAP/IL-1R3 Reference antibody (nidanilimab)
|
Interleukin Related
|
Cancer
|
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
|
-
-
- HY-P99451
-
-
-
- HY-P99166
-
|
XMAB-20717
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
|
-
-
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant antibody; Hu5c8
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P990952
-
|
OMS906
|
Ser/Thr Protease
Complement System
|
Metabolic Disease
Inflammation/Immunology
|
|
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .
|
-
-
- HY-P991564
-
|
IBI-343 antibody; HB37A6; TAK-921 antibody
|
ADC Antibody
Claudin
|
Cancer
|
|
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .
|
-
-
- HY-P991204
-
|
ARX517 antibody
|
PSMA
|
Cancer
|
|
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P9912A
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
-
- HY-P9969
-
|
EMD 72000
|
EGFR
|
Cancer
|
|
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab .
|
-
-
- HY-P99210
-
-
-
- HY-P99374
-
|
Anti-TSPAN26/CD37 Reference antibody (naratuximab)
|
ADC Antibody
|
Cancer
|
|
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
|
-
-
- HY-P99313
-
|
Anti-Human IGHE Recombinant antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
-
-
- HY-P99118
-
|
HLX 10
|
PD-1/PD-L1
Akt
STAT
|
Cancer
|
|
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .
|
-
-
- HY-P9947
-
|
|
Integrin
|
Others
|
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
|
-
-
- HY-P9960
-
|
2H7; PRO70769; RG1594
|
CD20
|
Inflammation/Immunology
|
|
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
|
-
-
- HY-P99363
-
|
Anti-ICOS/CD278 Reference antibody (feladilimab); GSK3359609
|
Transmembrane Glycoprotein
|
Cancer
|
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS/CD278 agonist monoclonal antibody. Feladilimab can be used for the research of cancer .
|
-
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
-
- HY-P99018
-
-
-
- HY-P99295
-
|
RG 7160; RO 5083945; Anti-EGFR Recombinant antibody
|
EGFR
|
Cancer
|
|
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
|
-
-
- HY-P99292
-
|
HuZAF; Anti-Human IFNG Recombinant antibody
|
IFNAR
|
Inflammation/Immunology
|
|
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
|
-
-
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
-
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
-
-
- HY-P99968
-
|
|
Mucin
|
Cancer
|
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .
|
-
-
- HY-P99854A
-
|
RC48-0 (powder)
|
EGFR
ADC Antibody
|
Cancer
|
|
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
|
-
-
- HY-P99310
-
|
RG4934
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
|
-
-
- HY-P99626
-
|
LY 3015014
|
PCSK9
|
Metabolic Disease
|
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
|
-
-
- HY-P99475
-
|
MSB-2311
|
PD-1/PD-L1
|
Cancer
|
|
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
|
-
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
-
- HY-P991190
-
|
AV-380
|
TGF-beta/Smad
|
Cancer
|
|
Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15 .
|
-
- HY-P990089
-
-
- HY-P99891
-
|
Hu23F2G
|
Integrin
|
Cardiovascular Disease
|
|
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
|
-
- HY-P990018
-
-
- HY-141602
-
-
- HY-P99027
-
|
LAG525; IMP701; Hu5A8
|
LAG-3
|
Cancer
|
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
|
-
- HY-P99888
-
|
|
EGFR
|
Others
|
|
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
|
-
- HY-P991644
-
|
|
Integrin
ADC Antibody
|
Cancer
|
|
IMGN388 Antibody is an Integrin targeting humanized monoclonal antibody. IMGN388 Antibody can be used for synthesis ADCs .
|
-
- HY-P99760
-
|
BCD-145
|
CTLA-4
|
Cancer
|
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
-
- HY-171270
-
|
|
Antibody-Drug Conjugates (ADCs)
Mucin
|
Cancer
|
|
Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) (Clivatuzumab antibody (HY-P99968), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is a humanized anti-mucin monoclonal antibody.
|
-
- HY-P990048
-
|
ADG126
|
CTLA-4
|
Cancer
|
|
Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic .
|
-
- HY-P991649
-
|
SAR566658 antibody
|
Mucin
ADC Antibody
|
Cancer
|
|
Anti-CA6 Antibody (huDS6) is a Mucin 1-associated sialoglycotope (CA6) targeting humanized monoclonal antibody. Anti-CA6 Antibody (huDS6) can be used for synthesis of ADCs .
|
-
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
-
- HY-P991581
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
MK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research .
|
-
- HY-147407
-
|
|
EGFR
|
Cancer
|
|
Imbotolimod, immunoglobulin G1-kappa, is a humanized monoclonal antibody with anti-ERBB2 and antineoplastic activity. Imbotolimod is a derivative of telratolimod .
|
-
- HY-P99773
-
|
JS002
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
|
-
- HY-P99442
-
|
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
-
- HY-P990020
-
|
FSI-174
|
c-Kit
|
Others
|
|
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .
|
-
- HY-P99558
-
|
GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX
|
EGFR
|
Cancer
|
|
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
|
-
- HY-P991188
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MGD007 is a humanized IgG1 monoclonal antibody targeting GPA33. MGD007 can be used for study of Metastatic Colorectal Cancer .
|
-
- HY-P991643
-
-
- HY-P991575
-
-
- HY-P991548
-
|
|
CD20
|
Inflammation/Immunology
Cancer
|
|
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .
|
-
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
- HY-P10544
-
|
|
Interleukin Related
|
Others
|
|
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .
|
-
- HY-P991625
-
|
|
VEGFR
|
Cancer
|
|
VX70 is a humanized monoclonal antibody inhibitor targeting VEGF-A. VX70 can be used for cancers research .
|
-
- HY-P991568
-
|
|
CXCR
|
Cancer
|
|
AT009 is an anti-CXCR4 humanized monoclonal antibody. AT009 can be used for cancer research .
|
-
- HY-P991286
-
-
- HY-P991287
-
-
- HY-P991177
-
|
RC-108 antibody
|
c-Met/HGFR
|
Cancer
|
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991259
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases .
|
-
- HY-P991519
-
-
- HY-P992110
-
|
DB-1311 antibody; BNT324 antibody
|
CD276/B7-H3
|
Cancer
|
|
Elfetabart (DB-1311 Antibody; BNT324 Antibody) is a humanized monoclonal antibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992134
-
|
|
Bacterial
|
Infection
|
|
Tepsababart is a humanized monoclonal antibody against staphylococcal clumping factor A, which can be used in research on antibacterial infections.
|
-
- HY-P992124
-
|
BAT8006 antibody; BAT-6028
|
Folate Receptor (FR)
|
Cancer
|
|
Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer .
|
-
- HY-P991903
-
|
|
CD20
|
Cancer
|
|
PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
|
-
- HY-P992486
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
XKH001 is a recombinant humanized IgG1 monoclonal antibody targeting IL-25. XKH001 has low immunogenicity. XKH001 can be used for the research of type 2 inflammatory diseases .
|
-
- HY-P992377
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
HY-0102 is a humanized IgG anti-NKG2A monoclonal antibody and immune checkpoint inhibitor targeting the NKG2A/HLA-E axis. HY-0102 is applicable for the research of advanced solid tumors .
|
-
- HY-P992111
-
|
UCB4594
|
MHC
|
Cancer
|
|
Elfritatug (UCB4594) is a humanized monoclonal antibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors .
|
-
- HY-P991950
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992166
-
|
|
ADC Antibody
Collagen
|
Cancer
|
|
AB-004 is a humanized monoclonal antibody and ADC targeting uPARAP. AB-004 can be conjugated with the topoisomerase-1 inhibitor P1021 via a protease-cleavable tetrapeptide linker to form the ADC ADCE-D01. AB-004 binds to tumor cells expressing uPARAP, triggering the endocytosis of the ADC. AB-004 is applicable for cancer research .
|
-
- HY-185683
-
|
DB-1311; BNT324
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
CD276/B7-H3
|
Cancer
|
|
Elfetabart drozuntecan (DB-1311; BNT324) is an antibody-drug conjugate (ADC) targeting B7H3. Elfetabart drozuntecan conjugates a humanized anti-B7H3 IgG1 monoclonal antibody with a topoisomerase I inhibitor via a cleavable linker. Elfetabart drozuntecan exerts antitumor activity in solid tumors. Elfetabart drozuntecan can be used for the research of advanced/metastatic solid tumors .
|
-
- HY-P992168
-
-
- HY-P992120
-
|
|
CCR
|
Inflammation/Immunology
|
|
Minokitug is a humanized monoclonal antibody targeting the CCR2 protein. Minokitug can be used for the research of refractory/relapsed ulcerative colitis .
|
-
- HY-P992054
-
|
|
VEGFR
|
Cardiovascular Disease
Cancer
|
|
APX004 is a humanized monoclonal antibody targeting-VEGF2. APX004 can be used for the research of cancers and angiogenic diseases.
|
-
- HY-P992044
-
-
- HY-P992427
-
-
- HY-P991578
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
SNG-8023 is an anti-ERα humanized monoclonal antibody. SNG-8023 can be used for cancer research, such as breast cancer .
|
-
- HY-P992334
-
|
|
CCR
|
Cancer
|
|
CM369 is a humanized monoclonal antibody against CCR8 that possesses potential immunomodulatory and anti-tumor activities. CM369 can be used in cancer research.
|
-
- HY-P991645
-
|
MDX-1203 antibody; BMS-936561 antibody
|
TNF Receptor
ADC Antibody
|
Cancer
|
|
MDX-1115 is a humanized IgG1 monoclonal antibody targeting CD70. MDX-1115 can be used for synthesis of ADC BMS-936561 .
|
-
- HY-P991658
-
|
ARGX-109; GB224; RYI-008
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .
|
-
- HY-P992480
-
-
- HY-P99629
-
|
FHTR 2163; RG 6147; RO 7171009
|
Ser/Thr Protease
|
Neurological Disease
|
|
Galegenimab (FHTR 2163) is a humanized monoclonal antibody Fab fragment targeting the HtrA1 trimer. Galegenimab is used in research on age-related macular degeneration (AMD) .
|
-
- HY-P99022
-
|
R-04909832; RG-1450
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
-
- HY-P992100
-
|
|
Annexin A
|
Cancer
|
|
Amesotatug is a humanized monoclonal antibody and ANXA1 binder. Amesotatug binds to Homo sapiens ANXA1 and exhibits antineoplastic activity. Amesotatug can be used for the research of cancer .
|
-
- HY-P99308
-
|
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant antibody
|
CD20
|
Cancer
|
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
|
-
- HY-P99634
-
|
PankoMab; DS-3939a antibody
|
Mucin
|
Cancer
|
|
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .
|
-
- HY-P990027
-
|
IMGC-936 antibody; MGA021
|
ADC Antibody
MMP
|
Cancer
|
|
Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
|
-
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
-
- HY-P991963
-
|
|
ERK
|
Others
|
|
Anti-Big-ET-1 Antibody is a humanized monoclonal antibody targeting Big-ET-1. Recommended Isotype Control: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99332
-
|
Anti-Human CD3E Recombinant antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
-
- HY-P992231
-
|
|
TAM Receptor
|
Inflammation/Immunology
|
|
Anti-GAS6 Antibody (KM5321) is a humanized anti-GAS6 monoclonal antibody. Its isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99250
-
|
MetMAb
|
c-Met/HGFR
|
Cancer
|
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
|
-
- HY-P991175
-
-
- HY-P992126
-
|
EYE-103; MK-3000
|
Wnt
|
Neurological Disease
|
|
Remigromig (EYE-103; MK-3000) is a humanized bispecific monoclonal antibody targeting LRP5 and FZD4, suitable for use in research related to macular degeneration .
|
-
- HY-P991179
-
|
|
TNF Receptor
|
Cancer
|
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
|
-
- HY-P991093
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
NGM-707 is a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors .
|
-
- HY-P992122
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Olevaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4, which can be used for the research of autoimmune diseases such as atopic dermatitis and alopecia areata .
|
-
- HY-P99835
-
|
MABT 5102A; RG 7412
|
Amyloid-β
|
Neurological Disease
|
|
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .
|
-
- HY-P992117
-
|
DCSZ-11
|
Complement System
|
Cancer
|
|
Lexucitug (DCSZ-11) is a humanized monoclonal antibody targeting CD93. The antibody isotype of Lexucitug is human IgG1κ; the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99334
-
|
Anti-Human CD70 Recombinant antibody; SGN-75
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
|
-
- HY-P991185
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991681
-
|
ASP-2138
|
Claudin
CD3
|
Cancer
|
|
Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research .
|
-
- HY-P99576
-
|
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
-
- HY-P992371
-
|
|
VEGFR
|
Cancer
|
|
hPV19 is a humanized inhibitory monoclonal antibody targeting vascular endothelial growth factor (VEGF) with a unique binding site. hPV19 can be used for the research of advanced solid tumors .
|
-
- HY-P990092
-
|
|
LILRB
Transmembrane Glycoprotein
|
Cancer
|
|
Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic .
|
-
- HY-P991591
-
|
|
Integrin
|
Inflammation/Immunology
|
|
MOR101 is a humanized monoclonal antibody inhibitor targeting ICAM-1/CD54. MOR101 can be used to study acute and chronic inflammation, such as burns .
|
-
- HY-P990714
-
|
|
CD3
|
Inflammation/Immunology
|
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
-
- HY-P992316
-
|
|
Claudin
ADC Antibody
|
Cancer
|
|
ATG-022 Antibody is a humanized monoclonal antibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer .
|
-
- HY-P991670
-
|
AVTX-009
|
Interleukin Related
|
Inflammation/Immunology
|
|
Abdakibart is a humanized IgG4 monoclonal antibody inhibitor targeting IL-1β. Abdakibart can be used for inflammatory disease like type 2 diabetes research .
|
-
- HY-P99906
-
|
DKN-01; LY-2812176
|
β-catenin
|
Cancer
|
|
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
|
-
- HY-P99370
-
|
LY2495655; Anti-GDF8 / Myostatin Reference antibody (landogrozumab)
|
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
|
-
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
-
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
-
- HY-P990028
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
|
-
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
-
- HY-P991269
-
|
|
Interleukin Related
|
Metabolic Disease
|
|
LY2189102 is a humanized monoclonal antibody inhibitor targeting interleukin-1β (IL-1β). LY2189102 is promising for research of type 2 diabetes .
|
-
- HY-P990036
-
|
PF-06823859
|
IFNAR
|
Inflammation/Immunology
|
|
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .
|
-
- HY-158109
-
|
|
Antibody-Drug Conjugates (ADCs)
CD2
Topoisomerase
|
Cancer
|
|
M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonal antibody hu14.18 (K322A) (HY-P991040) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .
|
-
- HY-P99644
-
ACT017
1 Publications Verification
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .
|
-
- HY-P99181
-
-
- HY-108739
-
|
BI 655075
|
Thrombin
|
Cardiovascular Disease
|
|
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
|
-
- HY-P990077
-
|
CT-011; MDV9300
|
PD-1/PD-L1
|
Cancer
|
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
|
-
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
-
- HY-P991726
-
|
|
Orphan GPCR
|
Cancer
|
|
Vemzatatug is a humanized IgG1κ monoclonal antibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
|
-
- HY-P991596
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .
|
-
- HY-132262
-
|
IMGN-901; BB-1090
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity .
|
-
- HY-P991666
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BMS-986090 is a humanized monoclonal antibody antagonist targeting CD40. BMS-986090 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS) .
|
-
- HY-P991721
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
|
-
- HY-P99053
-
-
- HY-P99849
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
|
-
- HY-P99857
-
|
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
-
- HY-P9966
-
|
MGA271
|
CD276/B7-H3
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
-
- HY-P992115
-
|
|
Integrin
|
Cancer
|
|
Furtisetabart is a humanized monoclonal antibody targeting CD147 with anti-tumor activity. Furtisetabart is of the human IgG4κ antibody subtype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P992116
-
|
|
TAM Receptor
|
Cancer
|
|
Ladarutatug is a humanized monoclonal antibody targeting Tyrosine-protein kinase receptor UFO. The Ladarutatug antibody isotype is human IgG4κ; the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P992118
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Lifonebart is a humanized monoclonal antibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). The antibody isotype of Lifonebart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992203
-
|
|
CD47
|
Others
|
|
Anti-CD172a Antibody (3F9) is a humanized IgG1 monoclonal antibody targeting SIRPα/CD172a. The recommended isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P991197
-
|
LM-305 antibody; AZD-0305 antibody
|
CD3
|
Cancer
|
|
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991552
-
|
|
CD3
|
Metabolic Disease
Inflammation/Immunology
|
|
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .
|
-
- HY-P991139
-
|
|
CTLA-4
|
Cancer
|
|
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
|
-
- HY-P991603
-
|
|
Integrin
|
Inflammation/Immunology
|
|
ASP5094 is a humanized monoclonal antibody against integrin alpha-9. ASP5094 has good safety and tolerability. ASP5094 can be used in the research of diseases such as rheumatoid arthritis .
|
-
- HY-P99401
-
|
OMP-131R10
|
Wnt
|
Cancer
|
|
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .
|
-
- HY-P991260
-
|
|
Interleukin Related
|
Infection
|
|
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
|
-
- HY-P99462
-
|
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
-
- HY-P991271
-
|
NNC-114-0005
|
Interleukin Related
|
Inflammation/Immunology
|
|
NN-8828 (NNC-114-0005) is a humanized monoclonal antibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
|
-
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
-
- HY-P991263
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
|
-
- HY-P991152
-
|
QX-005N
|
Interleukin Related
|
Inflammation/Immunology
|
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P99169
-
|
TJ004309
|
CD73
|
Cancer
|
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
|
-
- HY-P992235
-
-
- HY-P991187
-
|
AGX-101 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991075
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991281
-
-
- HY-P991604
-
|
YFC51.1; LDP-01
|
Integrin
|
Inflammation/Immunology
|
|
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
|
-
- HY-P991150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
|
-
- HY-P99295A
-
|
RG 7160 (FUT8-KO); RO 5083945 (FUT8-KO); Anti-EGFR Recombinant antibody (FUT8-KO)
|
EGFR
|
Cancer
|
|
Imgatuzumab (FUT8-KO) is a humanized monoclonal antibody against EGFR expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Imgatuzumab is an immunomodulator. Imgatuzumab may be used in cancer research.
|
-
- HY-P991723
-
|
CX-2051 antibody
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer .
|
-
- HY-P99285
-
|
hBU 12
|
ADC Antibody
CD19
|
Cancer
|
|
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
|
-
- HY-P99515
-
|
GR 1501
|
Interleukin Related
|
Inflammation/Immunology
|
|
Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade. Xeligekimab can be used for the research of inflammatory disease, such as radiographic axial spondyloarthritis .
|
-
- HY-P991265
-
|
|
Interleukin Related
|
Cancer
|
|
OSE-703 is a humanized monoclonal antibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases .
|
-
- HY-P991135
-
|
RO-7502175; RG-6411
|
CCR
|
Cancer
|
|
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
|
-
- HY-P99365
-
|
ALXN1210
|
Complement System
|
Metabolic Disease
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
-
- HY-P991711
-
|
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Povovetug is a humanized IgG1κ chimeric monoclonal antibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research .
|
-
- HY-P992355
-
|
GB7004-09hu15
|
Claudin
|
Cancer
|
|
GB7004-09 (GB7004-09hu15) is a humanized monoclonal antibody against CLDN18.2. GB7004-09 can be used in cancer research .
|
-
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
-
- HY-P991650
-
|
|
PSMA
|
Cancer
|
|
MDX1201 is a humanized monoclonal antibody targeting PSMA1/7. MDX1201 conjugated with a fluorescent dye AlexaTM488 can be used as a probe for near-infrared fluorescence imaging (NIRF) imaging of prostate cancer .
|
-
- HY-P991195
-
|
SIM1811-03
|
TNF Receptor
|
Cancer
|
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P99893
-
|
AMG-570
|
CD28
TNF Receptor
|
Inflammation/Immunology
|
|
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Rozibafusp alfa can be used for the research of systemic lupus erythematosus and other autoimmune diseases .
|
-
- HY-P991145
-
|
|
SLC39 (Zinc Transporter)
|
Cancer
|
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
-
- HY-P9944
-
|
MEDI 493
|
RSV
|
Infection
Inflammation/Immunology
Cancer
|
|
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
|
-
- HY-P991688
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
|
-
- HY-P99185
-
|
AAB-001
|
Amyloid-β
|
Neurological Disease
|
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
|
-
- HY-P991266
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .
|
-
- HY-P992123
-
|
AZD-5148
|
Bacterial
|
Infection
|
|
Ombetoxabart is a humanized IgG1-κ monoclonal antibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection .
|
-
- HY-P991690
-
|
|
RSV
|
Infection
|
|
Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
|
-
- HY-P991717
-
|
AZD-8630
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sunakiment is a humanized IgG1λ monoclonal antibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .
|
-
- HY-P991614
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
|
-
- HY-P990072
-
|
LZM-009
|
PD-1/PD-L1
|
Cancer
|
|
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
|
-
- HY-P3239
-
|
GSK2857916; Belantamab mafodotin-blm
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity .
|
-
- HY-145627
-
|
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
|
-
- HY-145636
-
|
AEX4089DC1; MGC018
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity .
|
-
- HY-P99015
-
|
|
TNF Receptor
|
Cancer
|
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
|
-
- HY-P99013
-
|
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
-
- HY-P991554
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
|
-
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
|
-
- HY-P991167
-
|
|
Bacterial
|
Infection
|
|
Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
|
-
- HY-P99439
-
|
IMA-638
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
|
-
- HY-P991608
-
|
7F11C7
|
Mucin
|
Cancer
|
|
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
|
-
- HY-P991635
-
|
|
TNF Receptor
|
Cancer
|
|
PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
|
-
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
-
- HY-P991258
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
|
-
- HY-P990070
-
|
BION-1301
|
TNF Receptor
|
|
|
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonal antibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .
|
-
- HY-P991892
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 is a humanized anti-CD4 monoclonal IgG1 antibody. IT1208 depletes CD4 + T cells with a manageable safety profile in vivo. IT1208 can be used for colon cancer research .
|
-
- HY-P991041
-
|
Anti-SEZ6 antibody (SC17); ABBV-011 antibody; ABBV-706 antibody
|
ADC Antibody
|
Cancer
|
|
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99471
-
|
UCB 0107
|
Tau Protein
|
Neurological Disease
|
|
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .
|
-
- HY-P991556
-
|
|
TNF Receptor
|
Cancer
|
|
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
|
-
- HY-P9953
-
|
Certolizumab; CDP870
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
|
-
- HY-P99513
-
|
CTB011
|
RABV
|
Infection
|
|
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
|
-
- HY-P992131
-
|
|
Mucin
|
Cancer
|
|
Sacomitatug is a humanized IgG1-κ monoclonal antibody targeting mucin 1 (MUC1). Sacomitatug exerts anti-tumor effects by blocking MUC1-mediated tumor proliferation signals and activating immune effectors .
|
-
- HY-P991285
-
-
- HY-P991659
-
|
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
SCH708980 is a humanized monoclonal antibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research .
|
-
- HY-P99904
-
|
MEDI-507; TCD601
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
|
-
- HY-P991652
-
|
RG-7594
|
Integrin
|
Cancer
|
|
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .
|
-
- HY-P991130
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
|
-
- HY-P9975
-
|
TGN1412; TAB08
|
CD28
|
Inflammation/Immunology
|
|
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
|
-
- HY-P991183
-
|
|
CD28
CD38
CD3
|
Cancer
|
|
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
|
-
- HY-P991619
-
|
TF8-5G9
|
Transmembrane Glycoprotein
|
Cancer
|
|
CNTO-860 is a humanized anti-tissue factor monoclonal antibody. CNTO-860 can improve tumor control when combined with Paclitaxel (HY-B0015) in colon cancer model and significantly increase tumor-free survival .
|
-
- HY-P991082
-
|
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991507
-
|
Demupitamab
|
EGFR
|
Cancer
|
|
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
|
-
- HY-P9968
-
|
h-R3
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-P99956
-
|
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
|
-
- HY-P9990
-
-
- HY-P991415
-
|
AM712
|
VEGFR
Tie
|
Others
|
|
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
-
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
|
-
- HY-P99540
-
|
PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
|
CTLA-4
|
Cancer
|
|
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991153
-
|
|
Virus Protease
|
Infection
|
|
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
|
-
- HY-P99028
-
|
TMB-355; TNX-355
|
HIV
|
Infection
|
|
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
|
-
- HY-P99858
-
|
AB154
|
Transmembrane Glycoprotein
|
Cancer
|
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
|
-
- HY-P991222
-
|
|
Phosphatase
|
Cardiovascular Disease
|
|
AMG-529 is a humanized monoclonal antibody against ASGR1 that binds to ASGR1, blocks ligand binding, and causes a dose-dependent increase in ALP (a biomarker of ASGR1 inhibition). AMG-529 can be used for the research of cardiovascular diseases .
|
-
- HY-P991589
-
|
NOV-1105
|
c-Met/HGFR
|
Cancer
|
|
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
|
-
- HY-P991612
-
|
Sym024
|
CD73
|
Inflammation/Immunology
Cancer
|
|
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
|
-
- HY-P991123
-
|
ALD1910; LU AG-09222
|
Adenylate Cyclase
|
Inflammation/Immunology
|
|
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
|
-
- HY-P990026A
-
-
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
-
- HY-P99886
-
|
h5G1. 1-SC
|
Complement System
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
|
-
- HY-P99172
-
|
|
CD47
Interleukin Related
|
Cancer
|
|
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
|
-
- HY-P992463
-
|
|
Ser/Thr Protease
|
Endocrinology
|
|
SHR-2010 is a fully humanized monoclonal antibody targeting MASP-2. SHR-2010 selectively inhibits lectin pathway activation without affecting classical or alternative complement pathways. SHR-2010 can be used for the research of IgA nephropathy .
|
-
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
- HY-P99112
-
|
RG-6168; SA-237
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
|
-
- HY-P991261
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
|
-
- HY-P990896
-
|
|
ADC Antibody
|
Cancer
|
|
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
|
-
- HY-P991174
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991638
-
|
|
TNF Receptor
|
Cancer
|
|
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
|
-
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991251
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
|
-
- HY-P992125
-
|
HFB-200603
|
CD28
|
Cancer
|
|
Radanstobart (HFB-200603) is a humanized monoclonal antibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991689
-
|
|
VEGFR
|
Cancer
|
|
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .
|
-
- HY-P990764B
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991647
-
|
|
CXCR
|
Cancer
|
|
ALX-0651 is a biparatopic humanized monoclonal antibody inhibitor targeting CXCR4. ALX-0651 inhibits hematopoietic stem cell trafficking, tumor progression and metastasis. ALX-0651 can be used for non-Hodgkin’s lymphoma and multiple myeloma research .
|
-
- HY-P99224
-
|
IMMU-106; hA20
|
Integrin
|
Cancer
|
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
|
-
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-171265
-
|
MRG003
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
|
-
- HY-P9968A
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-P992412
-
|
|
Claudin
|
Cancer
|
|
MIL93 is a humanized defucosylated IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
- HY-P99368
-
|
MCS110
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
|
-
- HY-P990007
-
|
PRA023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .
|
-
- HY-P99216
-
|
PF-04360365; RN 1219
|
Amyloid-β
|
Neurological Disease
|
|
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .
|
-
- HY-P9907A
-
|
Anti-Human HER2, Humanized antibody (anti-HER2)
|
ADC Antibody
EGFR
|
Cancer
|
|
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
- HY-P99317
-
|
LY-2062430
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .
|
-
- HY-P99215
-
|
Anti-EGFL7; RG 7414
|
VEGFR
|
Cancer
|
|
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
|
-
- HY-P992167
-
|
|
Claudin
|
Cancer
|
|
AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .
|
-
- HY-P99659
-
|
ANB 019
|
Interleukin Related
|
Inflammation/Immunology
|
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
|
-
- HY-P991993
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
AB054 is a humanized monoclonal antibody targeting factor XII (FXII). AB054 inhibits FXII activation and FXIIa activity through specific binding to the catalytic domain of FXII, and exerts antithrombotic effects in a concentration-dependent manner. AB054 can be used in studies related to thrombosis .
|
-
- HY-P990609
-
|
|
EGFR
|
Inflammation/Immunology
|
|
KHK-2866 is a recombinant humanized monoclonal antibody targeting heparin-binding epidermal growth factor-like growth factor (HB-EGF). The predicted molecular weight (MW) of KHK-2866 is 147.68 kDa. KHK-2866 can be used for tumor research .
|
-
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-P991282
-
|
|
Interleukin Related
|
Cancer
|
|
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
|
-
- HY-P991113
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
|
-
- HY-P991593
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
|
-
- HY-P99727
-
|
CTB012
|
RABV
|
Infection
|
|
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
|
-
- HY-P990022
-
|
DS-6016A
|
TGF-β Receptor
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .
|
-
- HY-P990051
-
|
AOC-1001 antibody; AOC-1044 antibody
|
Transferrin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Delpacibart is a humanized IgG1κ monoclonal antibody targeting the transferrin receptor TFRC. Delpacibart can be conjugated with the phosphorodiamidate morpholino oligonucleotide (PMO) Zotadirsen (HY-177972), which targets exon 44 of the dystrophin gene, to synthesize the antibody-oligonucleotide conjugate (AOC) Delpacibart zotadirsen (HY-177564). Delpacibart is suitable for use in Duchenne muscular dystrophy (DMD44) research .
|
-
- HY-P99101
-
|
AEX-4089; MGC026 antibody
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
|
-
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
-
- HY-185460
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
PI3K
mTOR
|
Cancer
|
|
Pertuzumab-LD3 is a humanized antibody-drug conjugate (ADC) targeting HER2. Pertuzumab-LD3 consists of the anti-HER2 humanized IgG1 monoclonal antibody Pertuzumab (HY-P9912), the cleavable linker Gly-Gly-Phe-Gly (HY-P3669), and the PI3K/mTOR-IN-21 (HY-185456) payload. Pertuzumab-LD3 can be used in research on metastatic HER2-positive breast cancer.
|
-
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
-
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
- HY-P991237
-
|
HMBD-001
|
EGFR
|
Cancer
|
|
Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
|
-
- HY-132253A
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-P991555
-
|
|
TNF Receptor
Apoptosis
|
Cancer
|
|
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
|
-
- HY-P991144
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
|
-
- HY-P991129
-
|
QX-002N
|
Interleukin Related
|
Inflammation/Immunology
|
|
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P99412
-
|
OSE-127
|
Interleukin Related
|
Cancer
|
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
|
-
- HY-P99162
-
|
CIM331; CD14152
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
-
- HY-P99050
-
|
BIVV009; IPN-009; TNT009
|
Complement System
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
|
-
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164152A
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
|
-
- HY-P991657
-
|
|
Complement System
|
Cardiovascular Disease
|
|
MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury .
|
-
- HY-P992436
-
|
|
Integrin
|
Neurological Disease
|
|
PAS-003 is a humanized monoclonal antibody targerting α5β1 integrin. PAS-003 modulates immune cell migration, immune cell adhesion, improves behavior, and improves survival in ALS mouse models. PAS-003 can be used for the research of amyotrophic lateral sclerosis .
|
-
- HY-P9951A
-
|
RG-6321 (anti-VEGF)
|
VEGFR
|
Cardiovascular Disease
|
|
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
|
-
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
-
- HY-P992132
-
|
STAR-0310
|
TNF Receptor
|
Inflammation/Immunology
|
|
Solaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4/OX40L. Solaprubart regulates immune homeostasis by blocking the OX40L-OX40 signaling pathway and can be used for the research of autoimmune diseases such as atopic dermatitis .
|
-
- HY-P992080
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is a humanized monoclonal antibody targeting H7N9. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) induces antibody-dependent cellular cytotoxicity (ADCC) against cells expressing H7N9 HA. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is applicable to studies related to H7N9 avian influenza virus infection .
|
-
- HY-P99901
-
|
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
|
-
- HY-P991250
-
|
|
Integrin
|
Cancer
|
|
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
|
-
- HY-P990025
-
|
ARGX-117
|
Complement System
|
Inflammation/Immunology
|
|
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
|
-
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
- HY-P991708
-
|
REGN-4336
|
PSMA
CD3
|
Cancer
|
|
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
|
-
- HY-P9950
-
|
Olizumab; rhuMab-E25; IGE25; RG-3648
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
|
-
- HY-P991066
-
|
ARGX-119
|
nAChR
|
Neurological Disease
|
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P991283
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
|
-
- HY-P991665
-
|
OBT357NF; OBT357
|
Transmembrane Glycoprotein
|
Cancer
|
|
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
|
-
- HY-P992508
-
|
SX001
|
Claudin
|
Cancer
|
|
SPX-101 (SX001) is a humanized monoclonal antibody targeting CLDN18.2. CLDN18.2 is only transiently expressed in the differentiated epithelial cells of the gastric mucosa and is hardly found in healthy tissues, thus having an extremely wide therapeutic window. SPX-101 can be used for the study of solid tumors.
|
-
- HY-P99345
-
|
TSR-042; ANB-011; WBP-285
|
PD-1/PD-L1
|
Cancer
|
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
-
- HY-P991636
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
|
-
- HY-P991052
-
|
|
TNF Receptor
|
Cancer
|
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990937
-
|
PF-04236921; TOUR-006
|
Interleukin Related
|
Inflammation/Immunology
|
|
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
|
-
- HY-P99037
-
|
M281
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
|
-
- HY-P99233
-
|
HuMax-TAC
|
ADC Antibody
Transmembrane Glycoprotein
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991588
-
|
AC101
|
EGFR
Apoptosis
|
Cancer
|
|
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
|
-
- HY-P99961
-
|
JS004; Icatolimab
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer .
|
-
- HY-P99493
-
|
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-P99252
-
|
Anti-Human CD6 Recombinant antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
-
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant antibody
|
CD28
Apoptosis
|
Cancer
|
|
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
|
-
- HY-P992376
-
|
NBE-002 antibody
|
ROR
|
Cancer
|
|
huXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonal antibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis) .
|
-
- HY-P99683
-
|
SGN-LIV1A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
|
-
- HY-P9918
-
|
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
-
- HY-P991363
-
|
|
Myosin
STAT
|
Inflammation/Immunology
|
|
AX-202 is a humanized IgG4 monoclonal antibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .
|
-
- HY-P99239
-
|
HUJ-591; TLX591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
-
- HY-P990071
-
|
LY-3016859
|
EGFR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .
|
-
- HY-P991173
-
|
|
Notch
|
Cancer
|
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991178
-
|
|
TNF Receptor
|
Cancer
|
|
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
|
-
- HY-P991569
-
|
|
Wnt
|
Metabolic Disease
Endocrinology
|
|
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
|
-
- HY-P99256
-
|
SCH 900222; MK 3222; Anti-Human IL23 Recombinant antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
|
-
- HY-P991151
-
|
|
PD-1/PD-L1
TNF Receptor
|
Cancer
|
|
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
|
-
- HY-P991574
-
|
REG-101
|
ATGL
|
Cardiovascular Disease
|
|
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
|
-
- HY-P9978
-
|
JS-001
|
PD-1/PD-L1
|
Cancer
|
|
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
|
-
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
|
-
- HY-P9948
-
|
Campath-IH
|
Apoptosis
|
Cancer
|
|
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
|
-
- HY-P99705
-
|
RG-7599; DNIB-0600A; NaPi2b-ADC
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research .
|
-
- HY-P990914
-
|
GS-1811; JTX-1811
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Denikitug (GS-1811; JTX-1811) is a humanized monoclonal antibody against CCR8 receptor with a KD of 16.8 pM. Denikitug specifically binds to human CCR8, inhibits CCL1-induced downstream CCR8 signaling. Denikitug selectively depletes cells expressing CCR8 via antibody-dependent cellular cytotoxicity (ADCC). Denikitug promotes anti-tumor immunity and can be used for the research of cancer and immunology .
|
-
- HY-P99866
-
|
MEHD-7945A; RG 7597
|
EGFR
Akt
p38 MAPK
Apoptosis
|
Cancer
|
|
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
|
-
- HY-P9983
-
|
SGN-33; HuM-195; GLK-33 antibody
|
Transmembrane Glycoprotein
Radionuclide-Drug Conjugates (RDCs)
|
Inflammation/Immunology
|
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
|
-
- HY-P991995
-
|
OMTX705 antibody
|
ADC Antibody
FAP
|
Cancer
|
|
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .
|
-
- HY-P99051
-
|
BAY 1834942
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
|
-
- HY-P990006
-
|
TEV-48574; SAR-447189; TEV-574
|
TNF Receptor
|
Inflammation/Immunology
|
|
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
-
- HY-P991957
-
|
|
Prion Protein
|
Neurological Disease
|
|
PRN100 is a fully humanized monoclonal antibody against cellular prion protein (PrPᶜ), belonging to the IgG4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.
|
-
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
- HY-P991244
-
|
|
EGFR
|
Cancer
|
|
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
|
-
- HY-P991246
-
|
|
Virus Protease
HIV
|
Infection
|
|
VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
|
-
- HY-P99525
-
|
R 84 (antibody); GNR-011
|
VEGFR
|
Cancer
|
|
Varisacumab (R 84; GNR-011) is a fully humanized IgG1 monoclonal antibody targeting VEGF. Varisacumab specifically blocks the interaction between VEGF and VEGFR2, but does not interfere with the interaction between VEGF and VEGFR1. Varisacumab achieves effective anti-tumor and anti-angiogenic effects and can be used in the research of non-small cell lung cancer and pancreatic cancer.
|
-
- HY-P991558
-
|
RG-7356
|
Transmembrane Glycoprotein
|
Cancer
|
|
RO-5429083 (RG-7356) is a humanized monoclonal antibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .
|
-
- HY-P990045
-
|
ALE.F02
|
Claudin
|
Endocrinology
|
|
Lixudebart (ALE.F02) is a humanized immunoglobulin G1-kappa, anti-CLDN1 monoclonal antibody. Lixudebart disrupts CLDN1 interactions with CD44 and MMP14, reduces renal macrophage infiltration, epithelial activation, and urinary albumin-to-creatinine ratio, and attenuates glomerulosclerosis. Lixudebart can be used for the research of focal segmental glomerulosclerosis .
|
-
- HY-P991653
-
|
|
CCR
HIV
|
Infection
|
|
HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research .
|
-
- HY-P991729
-
|
APG-777
|
Interleukin Related
|
Inflammation/Immunology
|
|
Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zumilokibart can be used for the research of atopic dermatitis (AD) .
|
-
- HY-P99304
-
|
Anti-Human ERBB3 Recombinant antibody
|
EGFR
PI3K
Akt
p38 MAPK
|
Cancer
|
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .
|
-
- HY-P992176
-
|
|
CD47
|
Cancer
|
|
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a Kd value of 11.0 × 10 -9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma .
|
-
- HY-P99045
-
|
HRS7; hRS7
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
- HY-P992346
-
|
|
CD47
|
Cancer
|
|
DS-1103a is a humanized IgG4 monoclonal antibody targeting SIRPa/CD172a. DS-1103a inhibits the interaction between SIRPα and CD47. DS-1103a enhances antibody-dependent cellular phagocytosis of cancer cells. DS-1103a can be used for the research of solid tumors. The recommended isotype control is: Human IgG4 (S228P) kappa, (HY-P99003) .
|
-
- HY-132258A
-
|
IMGN853 (solution)
|
Antibody-Drug Conjugates (ADCs)
Antifolate
|
Cancer
|
|
Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
|
-
- HY-P990730
-
|
ARB202
|
CD3
Cadherin
|
Cancer
|
|
Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers .
|
-
- HY-P99229
-
|
XMT-1535; Upinitatug
|
ADC Antibody
|
Cancer
|
|
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9907
-
Trastuzumab
Maximum Cited Publications
55 Publications Verification
Anti-Human HER2, Humanized antibody
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
ADC Antibody
|
Cancer
|
|
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
|
-
- HY-P990591
-
|
Aletekitug
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-1070806 (Aletekitug) is a humanized IgG1/κ monoclonal antibody targeting IL-18. GSK-1070806 neutralizes IL-18 activity.GSK-1070806 can be used for the research of inflammation. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99391
-
|
ABT-700; ABBV-400 antibody
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
-
- HY-P991272
-
|
PF-05230900
|
Interleukin Related
|
Inflammation/Immunology
|
|
ATR-107 (PF-05230900) is a humanized monoclonal antibody inhibitor that targets the interleukin-21 receptor (IL-21R). The Ka value of ATR-107 is 2-4 nM in cynomolgus monkeys, 16 nM in mice, and 71 nM in rats. ATR-107 can be used in research related to systemic lupus erythematosus and air pouch inflammation .
|
-
- HY-P991655
-
|
|
IFNAR
HIV
|
Infection
Inflammation/Immunology
|
|
AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
|
-
- HY-P9949
-
|
Sch 55700; CDP-835; JES1-39D10
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
-
- HY-P991240
-
|
KTN-3379
|
EGFR
|
Cancer
|
|
CDX-3379 is a humanized monoclonal antibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
|
-
- HY-P991651
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
|
-
- HY-P9929
-
|
BLA761046; MBL-CDB1; MDX-1388
|
Bacterial
|
Infection
|
|
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
|
-
- HY-P990753
-
|
CAN-106
|
Complement System
|
Inflammation/Immunology
|
|
Omoprubart is an anti-C5 complement recombinant humanized monoclonal antibody. Omolubat can prevent C5 from cleaving into C5a and C5b, thereby inhibiting the formation and activation of the C5b-dependent membrane attack complex (MAC) on the surface of susceptible cells, leading to cell lysis (destruction). Omoprubart can be used for the study of paroxysmal nocturnal hemoglobinuria (PNH).
|
-
- HY-P99731
-
|
hLL1; MEDI-115
|
CD74
|
Cancer
|
|
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
|
-
- HY-P991620
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
|
-
- HY-P992399
-
|
|
TNF Receptor
NF-κB
|
Cancer
|
|
LBL-019 is a humanized IgG1 monoclonal antibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P99414
-
|
AMG 557
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
|
|
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
- HY-P991146
-
|
LZM-012; XKH004
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P99492
-
|
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-P991534
-
|
|
Amyloid-β
|
Neurological Disease
|
|
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
|
-
- HY-P99045A
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
- HY-P99970
-
|
|
ADC Antibody
Sodium Phosphate Cotransporter
|
Cancer
|
|
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991892A
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
|
-
- HY-P991610
-
|
Sym025
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
|
-
- HY-P991542
-
|
|
CD19
|
Cancer
|
|
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
|
-
- HY-P991267
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CAN10 is is a humanized monoclonal antibody inhibitor targeting interleukin 1RAP (IL1RAP). CAN10 blocks IL-1, IL-33, and IL-36 signalling by targeting IL1RAP, preventing downstream proinflammatory and profibrotic responses. CAN10 reduces dermal and pulmonary fibrosis. CAN10 can be used for the research of immune system diseases, such as systemic sclerosis .
|
-
- HY-P99581
-
|
OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma .
|
-
- HY-P99009
-
|
RVT-1401; HBM9161; IMVT-1401
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
|
-
- HY-P992461
-
|
|
LAG-3
|
Cancer
|
|
SHR-1802 is a humanized anti-LAG-3 monoclonal antibody.SHR-1802 specifically binds to LAG-3 and inhibits its binding to major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin.SHR-1802 can be used for the research of advanced solid tumors .
|
-
- HY-P99391A
-
|
ABT-700 (powder)
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
- HY-P990061
-
|
JTX 8064
|
LILRB
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
|
-
- HY-P99199
-
|
NI-0401
|
CD3
|
Inflammation/Immunology
|
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
-
- HY-P992113
-
|
|
β-catenin
Wnt
|
Metabolic Disease
|
|
Evabosmig is a multispecific antibody targeting SOST, DKK-1 and ALB. Evabosmig can be used for the study of osteoporosis .
|
-
- HY-P992447
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .
|
-
- HY-P991294
-
|
|
ADC Antibody
|
Cancer
|
|
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
|
-
- HY-P991561
-
|
|
CD47
|
Cancer
|
|
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
|
-
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
-
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
-
- HY-P9924
-
|
LY2439821
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
|
-
- HY-P990667
-
|
BG00011
|
Integrin
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
STX-100 (BG00011) is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .
|
-
- HY-P991654
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
|
-
- HY-P99682
-
|
hLIV22
|
ADC Antibody
|
Cancer
|
|
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
|
-
- HY-P9972
-
|
PDR001
|
PD-1/PD-L1
IFNAR
|
Cancer
|
|
Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
|
-
- HY-P991220
-
|
|
TREM receptor
|
Neurological Disease
|
|
AL002 is a humanized monoclonal IgG1 antibody and a blood-brain barrier-permeable TREM2 modulator. AL002 binds to TREM2 on the surface of microglia, promotes TREM2 clustering and the formation of the TREM2-DAP12 complex, activates the TREM2 signaling pathway and PI3K cascade, and induces TREM2 internalization and degradation. AL002 is applicable to research related to Alzheimer's disease .
|
-
- HY-P991609
-
|
|
MMP
|
Cancer
|
|
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
|
-
- HY-P991572
-
|
|
EGFR
|
Cancer
|
|
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
|
-
- HY-P991867
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991201
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P99242
-
|
|
CD276/B7-H3
|
Cancer
|
|
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
|
-
- HY-P991633
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
|
-
- HY-P991720
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
|
-
- HY-P991646
-
|
heMab
|
Transmembrane Glycoprotein
|
Cancer
|
|
ING-1 (heMab) is a high-affinity humanized monoclonal antibody against epithelial cell adhesion molecule (Ep-CAM). ING-1 is a transmembrane glycoprotein mediating Ca 2+. ING-1 binds to Ep-CAM on tumor cells and exhibits potent in vitro activity, targeting and inhibiting tumor growth and metastasis in mouse cancer models. ING-1 is useful in the research of breast, colorectal, and lung cancers, among other cancers .
|
-
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
-
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
-
- HY-P99263
-
|
Anti-Human selectin P Recombinant antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
-
- HY-P991611
-
|
|
iGluR
|
Inflammation/Immunology
|
|
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
|
-
- HY-P991960
-
|
|
CTLA-4
Interleukin Related
|
Cancer
|
|
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
|
-
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
-
- HY-P99754
-
|
BCD-085
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99325
-
|
IDEC-131; Anti-Human CD40 ligand Recombinant antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
|
-
- HY-P991582
-
|
|
Fc Receptor (FcR)
|
Cancer
|
|
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
|
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99828
-
|
PF-06523435; hu24
|
ADC Antibody
RET
PERK
ROR
|
Cancer
|
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer .
|
-
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
- HY-P99613
-
|
MK-4280; Mavezelimab
|
LAG-3
|
Cancer
|
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma . For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P991570
-
|
AD5-10; oba-01 antibody
|
TNF Receptor
Apoptosis
Caspase
Atg8/LC3
Akt
Beclin1
JNK
|
Cancer
|
|
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models .
|
-
- HY-P992344
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
- HY-P99712
-
|
hz208F2-4
|
IGF-1R
Apoptosis
ADC Antibody
|
Cancer
|
|
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye
diseases .
|
-
- HY-P992367
-
|
|
TROP2
|
Cancer
|
|
hIMB1636 is a humanized monoclonal antibody targeting Trop2. By binding to the conformational Trop2 epitope, hIMB1636 regulates related signaling pathways, triggers lysosomal endocytosis, and further induces apoptosis, cell cycle arrest, and antibody-dependent cellular cytotoxicity. hIMB1636 effectively inhibits tumor cell proliferation, migration and in vivo tumor growth, and also exerts bystander killing effect and mediates long-term retention. hIMB1636 can be conjugated with NOTA/DOTA for radiolabeling to enable immuno-PET imaging, or prepared as hIMB1636-LDP-AE to significantly inhibit the growth of breast cancer and lung cancer xenografts .
|
-
- HY-P9980
-
|
GSK2857914
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
|
-
- HY-P991674
-
|
BJT-778
|
HBV
|
Infection
Inflammation/Immunology
|
|
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with Kd values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC50 values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .
|
-
- HY-P991480
-
|
|
Transmembrane Glycoprotein
Tau Protein
Amyloid-β
|
Neurological Disease
Cancer
|
|
ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease .
|
-
- HY-P991671
-
|
JNJ-80948543
|
CD3
CD20
Transmembrane Glycoprotein
|
Cancer
|
|
Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
|
-
- HY-P99809
-
|
MK-1308
|
CTLA-4
|
Cancer
|
|
Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
|
-
- HY-P991567
-
|
VX5/5261
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
|
-
- HY-P992023
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
APX002 is an anti-IL-1β humanized monoclonal antibody that binds to IL-1β with an affinity of 1.99×10 ?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis .
|
-
- HY-P991515
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
|
-
- HY-P99014
-
|
ARGX-110
|
Fc Receptor (FcR)
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
|
-
- HY-P991551
-
|
|
Dipeptidyl Peptidase
p38 MAPK
ERK
|
Infection
Cancer
|
|
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
|
-
- HY-P99404
-
|
E6011
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .
|
-
- HY-P991599
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991217
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
|
-
- HY-P991956
-
|
|
Transmembrane Glycoprotein
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
ABB071 is a humanized anti-CD180 monoclonal antibody. ABB071 can down-regulate the highly expressed TLR7 and IRF5 genes in systemic lupus erythematosus and induce the expression of PNPT1 and DNASE1L3 genes. ABB071 can inhibit the expression of genes related to the type I interferon pathway as well as interferon-stimulated genes (ISGs). ABB071 has anti-inflammatory activity and can reduce the levels of inflammatory cytokines. ABB071 can be used for research on systemic lupus erythematosus and psoriasis .
|
-
- HY-P991565
-
|
|
c-Met/HGFR
|
Cancer
|
|
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
|
-
- HY-P99019
-
|
TEV-48125; LBR-101; PF-04427429; RN-307
|
CGRP Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .
|
-
- HY-P991598
-
|
MOR12743; MOR03207
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
|
-
- HY-P3371
-
|
DS-7300a; MABX-9001a; I-DXd
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
Apoptosis
|
Cancer
|
|
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
|
-
- HY-P991223
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Cancer
|
|
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
|
-
- HY-P11084
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P11084A
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P99300
-
|
QGE 031; Anti-IGHE Recombinant antibody
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
|
-
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
- HY-P992388
-
|
|
LILRB
|
Cancer
|
|
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
|
-
- HY-P992381
-
|
|
Drug Derivative
|
Cancer
|
|
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
|
-
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P991634
-
|
|
CD73
TNF Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
|
-
- HY-P992372
-
|
|
Drug Derivative
Transmembrane Glycoprotein
|
Cancer
|
|
huAA98 is a humanized monoclonal antibody and also a CD146 inhibitor. huAA98 binds to human CD146, regulates its activity and inhibits cancer-related angiogenesis, as well as tube formation, motility, proliferation and migration of endothelial cells. huAA98 inhibits angiogenesis in the chick chorioallantoic membrane assay and reduces microvessel density in human tumor xenograft models. huAA98 shows immunoreactivity only to neovascular vessels within tumors and inhibits the growth of tumor xenograft models. huAA98 can be used in studies related to cancer-related angiogenesis, liver cancer, leiomyosarcoma and pancreatic cancer .
|
-
- HY-P991566
-
|
|
CTLA-4
|
Cancer
|
|
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
|
-
- HY-P991621
-
|
EOS-215
|
TREM receptor
|
Cancer
|
|
EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .
|
-
- HY-P992045
-
|
|
Interleukin Related
CXCR
|
Inflammation/Immunology
|
|
HZD37-5 is a humanized monoclonal antibody specifically recognizing N78 loci of IL-17A. HZD37-5 binds to human and rhesus monkeys, blocks IL-17 induced signal transduction and the release of IL-6, IL-8, CXCL-1 and GM-GSF. HZD37-5 significantly inhibited human IL-17A induced-keratinocyte chemoattractant secretion. HZD37-5 can be used for the research of autoimmune diseases including psoriasis and psoriatic arthritis .
|
-
- HY-P991656
-
|
|
CXCR
Apoptosis
p38 MAPK
Akt
|
Cancer
|
|
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
|
-
- HY-P991155
-
|
JNJ-79635322; JNJ-5322
|
CD3
TNF Receptor
|
Cancer
|
|
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
|
-
- HY-P991198
-
|
|
Tim3
|
Cancer
|
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
-
- HY-P991595
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P992172
-
|
|
Tau Protein
|
Neurological Disease
|
|
ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies .
|
-
- HY-P991444
-
|
|
NTPDase
ATP Synthase
|
Inflammation/Immunology
Cancer
|
|
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors .
|
-
- HY-P991584
-
|
|
FGFR
|
Cancer
|
|
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
|
-
- HY-108738
-
|
Ro 24-7375
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
|
-
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P992380
-
|
|
PD-1/PD-L1
|
Neurological Disease
|
|
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .
|
-
- HY-P99157
-
|
|
CD276/B7-H3
|
Cancer
|
|
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
|
-
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Neurological Disease
|
|
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
|
-
- HY-P99395
-
|
JNJ 56022473; CSL 362
|
Interleukin Related
|
Cancer
|
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
|
-
- HY-P992340
-
|
|
Radionuclide-Drug Conjugates (RDCs)
TNF Receptor
|
Cancer
|
|
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .
|
-
- HY-P992382
-
|
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003 .
|
-
- HY-P990093
-
|
CM310
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .
|
-
- HY-P992356
-
|
|
Topoisomerase
|
Cancer
|
|
GENA-104A16 is a humanized monoclonal antibody targeting CNTN4, with multiple functions including immunostimulation, cytotoxicity and immunoregulation. By binding to CNTN4, GENA-104A16 blocks its interaction with APP, thereby restoring T cell function, inducing tumor cell death and regulating tumor-infiltrating immune cell populations. GENA-104A16 also exerts topoisomerase I inhibitory activity via the payload Exatecan (HY-13631). GENA-104A16 can be used in research related to colon cancer liver metastasis and other CNTN4-expressing solid tumors .
|
-
- HY-P991927
-
|
|
CD47
|
Cancer
|
|
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
|
-
- HY-P992434
-
|
|
PD-1/PD-L1
SHP1
Interleukin Related
|
Cancer
|
|
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .
|
-
- HY-P99488
-
|
JSP-191; AMG-191
|
c-Kit
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
|
-
- HY-P99048A
-
|
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P99496
-
|
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
-
- HY-177442
-
|
DS-3939
|
Antibody-Drug Conjugates (ADCs)
Mucin
Topoisomerase
Apoptosis
|
Cancer
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-P991959
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
JMW-3B3 is a humanized IgG1λ monoclonal antibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.
|
-
- HY-P991193
-
|
|
TNF Receptor
|
Cancer
|
|
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a Ka of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 + T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .
|
-
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
|
-
- HY-108831A
-
|
AN100226; BG00002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-P3371
-
|
DS-7300a; MABX-9001a; I-DXd
|
Fluorescent Dyes
|
|
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
|
-
- HY-164153
-
|
|
Fluorescent Dyes
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-132253
-
|
|
Fluorescent Dyes
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-164152A
-
|
|
Fluorescent Dyes
|
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-171135
-
|
|
Fluorescent Dyes
|
|
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .
|
-
- HY-171265
-
|
MRG003
|
Fluorescent Dyes
|
|
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575) .
|
-
- HY-164152
-
|
|
Fluorescent Dyes
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-177442
-
|
DS-3939
|
Fluorescent Dyes
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-132253A
-
|
|
Fluorescent Dyes
|
|
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-158109
-
|
|
Fluorescent Dyes
|
|
M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonal antibody hu14.18 (K322A) (HY-P991040) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .
|
-
- HY-164154
-
|
|
Fluorescent Dyes
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P11084
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .
|
-
- HY-P10544
-
|
|
Interleukin Related
|
Others
|
|
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .
|
-
- HY-P11084A
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P9906
-
|
Anti-Human VEGF, Humanized antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
-
(5)
-
- HY-P99001
-
-
(5)
-
- HY-P99859
-
|
LY3002813
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
|
-
(5)
-
- HY-P99003
-
-
(5)
-
- HY-P9906A
-
|
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
|
-
(5)
-
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized antibody; LDP-02; MLN-002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
(5)
-
- HY-P9912
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
(5)
-
- HY-P9910
-
|
GA101; Anti-Human CD20 type II, Humanized antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
-
(5)
-
- HY-P9981
-
|
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
-
(5)
-
- HY-P9914
-
|
Anti-Human C5, Humanized antibody; h5G1.1
|
Complement System
|
Cardiovascular Disease
Neurological Disease
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
|
-
(5)
-
- HY-P9952
-
|
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
|
-
(5)
-
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
|
-
(5)
-
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
(5)
-
- HY-P99372
-
|
Anti-NCAM1/ CD56 Reference antibody (lorvotuzumab)
|
ADC Antibody
|
Cancer
|
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
|
-
(5)
-
- HY-P99043
-
|
SC-0001
|
Notch
|
Cancer
|
|
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
|
-
(5)
-
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
(5)
-
- HY-P99854
-
|
RC48-0
|
EGFR
ADC Antibody
|
Cancer
|
|
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
|
-
(5)
-
- HY-P99329
-
|
Anti-Human CD33 Recombinant antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
|
-
(5)
-
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
-
(5)
-
- HY-P9945
-
|
SB 240563
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
(5)
-
- HY-P99509
-
-
(5)
-
- HY-P99153
-
|
MORAb-003
|
Antibiotic
|
Cancer
|
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
|
-
(5)
-
- HY-P9945A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
(5)
-
- HY-P99206
-
|
Naxitamab-gqgk; Humanized 3F8; Hu3F8
|
Inhibitory Antibodies
|
Cancer
|
|
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers .
|
-
(5)
-
- HY-P99379
-
|
CAN04; Anti-IL-1RAP/IL-1R3 Reference antibody (nidanilimab)
|
Interleukin Related
|
Cancer
|
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
|
-
(5)
-
- HY-P99451
-
-
(5)
-
- HY-P99166
-
|
XMAB-20717
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
|
-
(5)
-
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant antibody; Hu5c8
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P990952
-
|
OMS906
|
Ser/Thr Protease
Complement System
|
Metabolic Disease
Inflammation/Immunology
|
|
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .
|
-
(5)
-
- HY-P991206
-
-
(5)
-
- HY-P991564
-
|
IBI-343 antibody; HB37A6; TAK-921 antibody
|
ADC Antibody
Claudin
|
Cancer
|
|
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .
|
-
(5)
-
- HY-P9969
-
|
EMD 72000
|
EGFR
|
Cancer
|
|
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab .
|
-
(5)
-
- HY-P99210
-
-
(5)
-
- HY-P99374
-
|
Anti-TSPAN26/CD37 Reference antibody (naratuximab)
|
ADC Antibody
|
Cancer
|
|
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
|
-
(5)
-
- HY-P99313
-
|
Anti-Human IGHE Recombinant antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
-
(5)
-
- HY-P99118
-
|
HLX 10
|
PD-1/PD-L1
Akt
STAT
|
Cancer
|
|
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer .
|
-
(5)
-
- HY-P9947
-
|
|
Integrin
|
Others
|
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
|
-
(5)
-
- HY-P99400
-
|
ALXN 6000
|
Inhibitory Antibodies
|
Cancer
|
|
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research .
|
-
(5)
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
(5)
-
- HY-P99018
-
-
(5)
-
- HY-P99295
-
|
RG 7160; RO 5083945; Anti-EGFR Recombinant antibody
|
EGFR
|
Cancer
|
|
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
|
-
(5)
-
- HY-P99292
-
|
HuZAF; Anti-Human IFNG Recombinant antibody
|
IFNAR
|
Inflammation/Immunology
|
|
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
|
-
(5)
-
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
(5)
-
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
-
(5)
-
- HY-P991207
-
-
(5)
-
- HY-P99968
-
|
|
Mucin
|
Cancer
|
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .
|
-
(5)
-
- HY-P99801
-
-
(5)
-
- HY-P99854A
-
|
RC48-0 (powder)
|
EGFR
ADC Antibody
|
Cancer
|
|
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
|
-
(5)
-
- HY-P99267
-
|
RhuMab IFNalpha; Anti-Human IFN alpha Recombinant antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].
|
-
(5)
-
- HY-P99310
-
|
RG4934
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
|
-
(5)
- HY-P99626
-
|
LY 3015014
|
PCSK9
|
Metabolic Disease
|
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
|
-
(5)
- HY-P99475
-
|
MSB-2311
|
PD-1/PD-L1
|
Cancer
|
|
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
|
-
(5)
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
-
(5)
- HY-P99875
-
|
BIVV-001; Altuvoct
|
Inhibitory Antibodies
|
Cardiovascular Disease
|
|
Efanesoctocog alfa is a B domain-deleted single-chain Factor VIII (FVIII) connected to D'D3 domain of von Willebrand Factor (vWF). Efanesoctocog alfa has an extended half-life. Efanesoctocog alfa can be used for the study of inherited hemophilia A .
|
-
(5)
- HY-P991190
-
|
AV-380
|
TGF-beta/Smad
|
Cancer
|
|
Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15 .
|
-
(5)
- HY-P99212
-
|
TRU-016
|
Inhibitory Antibodies
|
Cancer
|
|
Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research .
|
-
(5)
- HY-P990089
-
-
(5)
- HY-P99891
-
|
Hu23F2G
|
Integrin
|
Cardiovascular Disease
|
|
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
|
-
(5)
- HY-P990018
-
-
(5)
- HY-P99027
-
|
LAG525; IMP701; Hu5A8
|
LAG-3
|
Cancer
|
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
|
-
(5)
- HY-P99403
-
|
GSK249320
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Refanezumab (GSK249320) is a brain-penetrant IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab has the potential for the enhancement of recovery of function poststroke .
|
-
(5)
- HY-P99888
-
|
|
EGFR
|
Others
|
|
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
|
-
(5)
- HY-P991644
-
|
|
Integrin
ADC Antibody
|
Cancer
|
|
IMGN388 Antibody is an Integrin targeting humanized monoclonal antibody. IMGN388 Antibody can be used for synthesis ADCs .
|
-
(5)
- HY-P99760
-
|
BCD-145
|
CTLA-4
|
Cancer
|
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
-
(5)
- HY-P990048
-
|
ADG126
|
CTLA-4
|
Cancer
|
|
Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic .
|
-
(5)
- HY-P991649
-
|
SAR566658 antibody
|
Mucin
ADC Antibody
|
Cancer
|
|
Anti-CA6 Antibody (huDS6) is a Mucin 1-associated sialoglycotope (CA6) targeting humanized monoclonal antibody. Anti-CA6 Antibody (huDS6) can be used for synthesis of ADCs .
|
-
(5)
- HY-P99582
-
|
ONC-005, OTSA101
|
Inhibitory Antibodies
|
Cancer
|
|
Tabituximab (OTSA101) is a humanized monoclonal antibody against frizzled class receptor 10 (FZD10) .
|
-
(5)
- HY-P991667
-
-
(5)
- HY-P991581
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
MK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research .
|
-
(5)
- HY-P99773
-
|
JS002
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
|
-
(5)
- HY-P99442
-
|
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
-
(5)
- HY-P990020
-
|
FSI-174
|
c-Kit
|
Others
|
|
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .
|
-
(5)
- HY-P99558
-
|
GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX
|
EGFR
|
Cancer
|
|
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
|
-
(5)
- HY-P991188
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MGD007 is a humanized IgG1 monoclonal antibody targeting GPA33. MGD007 can be used for study of Metastatic Colorectal Cancer .
|
-
(5)
- HY-P991548
-
|
|
CD20
|
Inflammation/Immunology
Cancer
|
|
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .
|
-
(5)
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
(5)
- HY-P99319
-
-
(5)
- HY-P990039
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Falbikitug is a humanized immunoglobulin G1-kappa, anti-LIF monoclonal antibody. Falbikitug is an antineoplastic .
|
-
(5)
- HY-P991625
-
|
|
VEGFR
|
Cancer
|
|
VX70 is a humanized monoclonal antibody inhibitor targeting VEGF-A. VX70 can be used for cancers research .
|
-
(5)
- HY-P991568
-
|
|
CXCR
|
Cancer
|
|
AT009 is an anti-CXCR4 humanized monoclonal antibody. AT009 can be used for cancer research .
|
-
(5)
- HY-P991286
-
-
(5)
- HY-P991287
-
-
(5)
- HY-P991177
-
|
RC-108 antibody
|
c-Met/HGFR
|
Cancer
|
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P992110
-
|
DB-1311 antibody; BNT324 antibody
|
CD276/B7-H3
|
Cancer
|
|
Elfetabart (DB-1311 Antibody; BNT324 Antibody) is a humanized monoclonal antibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992134
-
|
|
Bacterial
|
Infection
|
|
Tepsababart is a humanized monoclonal antibody against staphylococcal clumping factor A, which can be used in research on antibacterial infections.
|
-
(5)
- HY-P992124
-
|
BAT8006 antibody; BAT-6028
|
Folate Receptor (FR)
|
Cancer
|
|
Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer .
|
-
(5)
- HY-P991903
-
|
|
CD20
|
Cancer
|
|
PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
|
-
(5)
- HY-P992486
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
XKH001 is a recombinant humanized IgG1 monoclonal antibody targeting IL-25. XKH001 has low immunogenicity. XKH001 can be used for the research of type 2 inflammatory diseases .
|
-
(5)
- HY-P992377
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
HY-0102 is a humanized IgG anti-NKG2A monoclonal antibody and immune checkpoint inhibitor targeting the NKG2A/HLA-E axis. HY-0102 is applicable for the research of advanced solid tumors .
|
-
(5)
- HY-P992452
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
RO-5469754 is a humanized monoclonal antibody that specifically binds to human thymic stromal lymphopoietin (TSLP). RO-5469754 blocks the binding of hTSLP to its receptor complex, thereby neutralizing TSLP-mediated biological activities, and does not cross-react with TSLP from cynomolgus monkeys or mice. RO-5469754 can be further used to generate the bispecific antibody TAVO101 × IL4R-dupi .
|
-
(5)
- HY-P992111
-
|
UCB4594
|
MHC
|
Cancer
|
|
Elfritatug (UCB4594) is a humanized monoclonal antibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors .
|
-
(5)
- HY-P991950
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992166
-
|
|
ADC Antibody
Collagen
|
Cancer
|
|
AB-004 is a humanized monoclonal antibody and ADC targeting uPARAP. AB-004 can be conjugated with the topoisomerase-1 inhibitor P1021 via a protease-cleavable tetrapeptide linker to form the ADC ADCE-D01. AB-004 binds to tumor cells expressing uPARAP, triggering the endocytosis of the ADC. AB-004 is applicable for cancer research .
|
-
(5)
- HY-P992168
-
-
(5)
- HY-P992120
-
|
|
CCR
|
Inflammation/Immunology
|
|
Minokitug is a humanized monoclonal antibody targeting the CCR2 protein. Minokitug can be used for the research of refractory/relapsed ulcerative colitis .
|
-
(5)
- HY-P992054
-
|
|
VEGFR
|
Cardiovascular Disease
Cancer
|
|
APX004 is a humanized monoclonal antibody targeting-VEGF2. APX004 can be used for the research of cancers and angiogenic diseases.
|
-
(5)
- HY-P992044
-
-
(5)
- HY-P992427
-
-
(5)
- HY-P991578
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
SNG-8023 is an anti-ERα humanized monoclonal antibody. SNG-8023 can be used for cancer research, such as breast cancer .
|
-
(5)
- HY-P992334
-
|
|
CCR
|
Cancer
|
|
CM369 is a humanized monoclonal antibody against CCR8 that possesses potential immunomodulatory and anti-tumor activities. CM369 can be used in cancer research.
|
-
(5)
- HY-P991643
-
-
(5)
- HY-P99658
-
|
PRX-003
|
Inhibitory Antibodies
|
Cancer
|
|
Imaprelimab (PRX-003) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody. Imaprelimab is an antineoplastic agent .
|
-
(5)
- HY-P9960
-
|
2H7; PRO70769; RG1594
|
CD20
|
Inflammation/Immunology
|
|
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
|
-
(5)
- HY-P991204
-
|
ARX517 antibody
|
PSMA
|
Cancer
|
|
Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991575
-
-
(5)
- HY-P991259
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases .
|
-
(5)
- HY-P9912A
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
(5)
- HY-P991519
-
-
(5)
- HY-P9904
-
|
MPDL3280A; RG-7446; RO-5541267
|
PD-1/PD-L1
Apoptosis
Autophagy
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
-
(5)
- HY-P9982
-
|
AMG-785; CDP-7851
|
Inhibitory Antibodies
|
Endocrinology
Cancer
|
|
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .
|
-
(5)
- HY-P99363
-
|
Anti-ICOS/CD278 Reference antibody (feladilimab); GSK3359609
|
Transmembrane Glycoprotein
|
Cancer
|
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS/CD278 agonist monoclonal antibody. Feladilimab can be used for the research of cancer .
|
-
(5)
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
-
(5)
- HY-P990081
-
|
TB-006
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Oloctinebart is a humanized immunoglobulin G4-kappa, anti-LGALS3 monoclonal antibody. Oloctinebart is used for reduction of amyloid beta oligomers formation .
|
-
(5)
- HY-P991645
-
|
MDX-1203 antibody; BMS-936561 antibody
|
TNF Receptor
ADC Antibody
|
Cancer
|
|
MDX-1115 is a humanized IgG1 monoclonal antibody targeting CD70. MDX-1115 can be used for synthesis of ADC BMS-936561 .
|
-
(5)
- HY-P991658
-
|
ARGX-109; GB224; RYI-008
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .
|
-
(5)
- HY-P992480
-
-
(5)
- HY-P99629
-
|
FHTR 2163; RG 6147; RO 7171009
|
Ser/Thr Protease
|
Neurological Disease
|
|
Galegenimab (FHTR 2163) is a humanized monoclonal antibody Fab fragment targeting the HtrA1 trimer. Galegenimab is used in research on age-related macular degeneration (AMD) .
|
-
(5)
- HY-P99022
-
|
R-04909832; RG-1450
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
-
(5)
- HY-P992100
-
|
|
Annexin A
|
Cancer
|
|
Amesotatug is a humanized monoclonal antibody and ANXA1 binder. Amesotatug binds to Homo sapiens ANXA1 and exhibits antineoplastic activity. Amesotatug can be used for the research of cancer .
|
-
(5)
- HY-P99570
-
|
GBR-830
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases .
|
-
(5)
- HY-P99308
-
|
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant antibody
|
CD20
|
Cancer
|
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
|
-
(5)
- HY-P99634
-
|
PankoMab; DS-3939a antibody
|
Mucin
|
Cancer
|
|
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .
|
-
(5)
- HY-P990027
-
|
IMGC-936 antibody; MGA021
|
ADC Antibody
MMP
|
Cancer
|
|
Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
|
-
(5)
- HY-P991230
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
MK-4830 is a fully humanized monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to ILT4 and blocks its interaction with HLA-G and other ligands. MK-4830 inhibits tumor growth in humanized mouse cancer models .
|
-
(5)
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
-
(5)
- HY-P99002
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Human IgG2 kappa, Isotype Control is a human monoclonal antibody serving as an isotype control for human IgG2κ antibodies such as Cepeprubart (HY-P990732) and Ersodetug (HY-P990712). Human IgG2 kappa, Isotype Control can be used in T cell research .
|
-
(5)
- HY-P991963
-
|
|
ERK
|
Others
|
|
Anti-Big-ET-1 Antibody is a humanized monoclonal antibody targeting Big-ET-1. Recommended Isotype Control: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P99332
-
|
Anti-Human CD3E Recombinant antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
-
(5)
- HY-P992231
-
|
|
TAM Receptor
|
Inflammation/Immunology
|
|
Anti-GAS6 Antibody (KM5321) is a humanized anti-GAS6 monoclonal antibody. Its isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P99250
-
|
MetMAb
|
c-Met/HGFR
|
Cancer
|
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
|
-
(5)
- HY-P991175
-
-
(5)
- HY-P992126
-
|
EYE-103; MK-3000
|
Wnt
|
Neurological Disease
|
|
Remigromig (EYE-103; MK-3000) is a humanized bispecific monoclonal antibody targeting LRP5 and FZD4, suitable for use in research related to macular degeneration .
|
-
(5)
- HY-P991179
-
|
|
TNF Receptor
|
Cancer
|
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
|
-
(5)
- HY-P991093
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
NGM-707 is a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors .
|
-
(5)
- HY-P992122
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Olevaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4, which can be used for the research of autoimmune diseases such as atopic dermatitis and alopecia areata .
|
-
(5)
- HY-P99835
-
|
MABT 5102A; RG 7412
|
Amyloid-β
|
Neurological Disease
|
|
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .
|
-
(5)
- HY-P992117
-
|
DCSZ-11
|
Complement System
|
Cancer
|
|
Lexucitug (DCSZ-11) is a humanized monoclonal antibody targeting CD93. The antibody isotype of Lexucitug is human IgG1κ; the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99334
-
|
Anti-Human CD70 Recombinant antibody; SGN-75
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
|
-
(5)
- HY-P99281
-
|
BIWA 4; Anti-CD44 Recombinant antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells .
|
-
(5)
- HY-P991185
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991681
-
|
ASP-2138
|
Claudin
CD3
|
Cancer
|
|
Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research .
|
-
(5)
- HY-P99576
-
|
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
-
(5)
- HY-P99571
-
|
INH-H 2002
|
Inhibitory Antibodies
|
Infection
|
|
Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections .
|
-
(5)
- HY-P992371
-
|
|
VEGFR
|
Cancer
|
|
hPV19 is a humanized inhibitory monoclonal antibody targeting vascular endothelial growth factor (VEGF) with a unique binding site. hPV19 can be used for the research of advanced solid tumors .
|
-
(5)
- HY-P990092
-
|
|
LILRB
Transmembrane Glycoprotein
|
Cancer
|
|
Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic .
|
-
(5)
- HY-P991591
-
|
|
Integrin
|
Inflammation/Immunology
|
|
MOR101 is a humanized monoclonal antibody inhibitor targeting ICAM-1/CD54. MOR101 can be used to study acute and chronic inflammation, such as burns .
|
-
(5)
- HY-P990714
-
|
|
CD3
|
Inflammation/Immunology
|
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
-
(5)
- HY-P992316
-
|
|
Claudin
ADC Antibody
|
Cancer
|
|
ATG-022 Antibody is a humanized monoclonal antibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer .
|
-
(5)
- HY-P991670
-
|
AVTX-009
|
Interleukin Related
|
Inflammation/Immunology
|
|
Abdakibart is a humanized IgG4 monoclonal antibody inhibitor targeting IL-1β. Abdakibart can be used for inflammatory disease like type 2 diabetes research .
|
-
(5)
- HY-P99906
-
|
DKN-01; LY-2812176
|
β-catenin
|
Cancer
|
|
Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1 .
|
-
(5)
- HY-P99370
-
|
LY2495655; Anti-GDF8 / Myostatin Reference antibody (landogrozumab)
|
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
|
-
(5)
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
-
(5)
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
-
(5)
- HY-P990028
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734) .
|
-
(5)
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
-
(5)
- HY-P991269
-
|
|
Interleukin Related
|
Metabolic Disease
|
|
LY2189102 is a humanized monoclonal antibody inhibitor targeting interleukin-1β (IL-1β). LY2189102 is promising for research of type 2 diabetes .
|
-
(5)
- HY-P990036
-
|
PF-06823859
|
IFNAR
|
Inflammation/Immunology
|
|
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis .
|
-
(5)
- HY-P990762
-
|
BCD-180
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Seniprutug (BCD-180) is a humanized monoclonal antibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9 + T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis .
|
-
(5)
- HY-P99644
-
ACT017
1 Publications Verification
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .
|
-
(5)
- HY-P99181
-
-
(5)
- HY-108739
-
|
BI 655075
|
Thrombin
|
Cardiovascular Disease
|
|
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
|
-
(5)
- HY-P990077
-
|
CT-011; MDV9300
|
PD-1/PD-L1
|
Cancer
|
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
|
-
(5)
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
-
(5)
- HY-P991726
-
|
|
Orphan GPCR
|
Cancer
|
|
Vemzatatug is a humanized IgG1κ monoclonal antibody inhibitor targeting GPRC5D. Vemzatatug has an antitumor activity. Vemzatatug can be used for cancers like multiple myeloma (MM) research .
|
-
(5)
- HY-P991596
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .
|
-
(5)
- HY-P991666
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BMS-986090 is a humanized monoclonal antibody antagonist targeting CD40. BMS-986090 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS) .
|
-
(5)
- HY-P991721
-
|
|
PCSK9
|
Cardiovascular Disease
|
|
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research .
|
-
(5)
- HY-P99053
-
-
(5)
- HY-P99849
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
|
-
(5)
- HY-P99857
-
|
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
-
(5)
- HY-P9966
-
|
MGA271
|
CD276/B7-H3
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
-
(5)
- HY-P992115
-
|
|
Integrin
|
Cancer
|
|
Furtisetabart is a humanized monoclonal antibody targeting CD147 with anti-tumor activity. Furtisetabart is of the human IgG4κ antibody subtype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P992116
-
|
|
TAM Receptor
|
Cancer
|
|
Ladarutatug is a humanized monoclonal antibody targeting Tyrosine-protein kinase receptor UFO. The Ladarutatug antibody isotype is human IgG4κ; the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P992118
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Lifonebart is a humanized monoclonal antibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). The antibody isotype of Lifonebart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992203
-
|
|
CD47
|
Others
|
|
Anti-CD172a Antibody (3F9) is a humanized IgG1 monoclonal antibody targeting SIRPα/CD172a. The recommended isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
(5)
- HY-P991197
-
|
LM-305 antibody; AZD-0305 antibody
|
CD3
|
Cancer
|
|
Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991552
-
|
|
CD3
|
Metabolic Disease
Inflammation/Immunology
|
|
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .
|
-
(5)
- HY-P991139
-
|
|
CTLA-4
|
Cancer
|
|
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
|
-
(5)
- HY-P991603
-
|
|
Integrin
|
Inflammation/Immunology
|
|
ASP5094 is a humanized monoclonal antibody against integrin alpha-9. ASP5094 has good safety and tolerability. ASP5094 can be used in the research of diseases such as rheumatoid arthritis .
|
-
(5)
- HY-P99401
-
|
OMP-131R10
|
Wnt
|
Cancer
|
|
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .
|
-
(5)
- HY-P991260
-
|
|
Interleukin Related
|
Infection
|
|
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
|
-
(5)
- HY-P99462
-
|
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
-
(5)
- HY-P991271
-
|
NNC-114-0005
|
Interleukin Related
|
Inflammation/Immunology
|
|
NN-8828 (NNC-114-0005) is a humanized monoclonal antibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
|
-
(5)
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
-
(5)
- HY-P991263
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
|
-
(5)
- HY-P991152
-
|
QX-005N
|
Interleukin Related
|
Inflammation/Immunology
|
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
-
(5)
- HY-P99169
-
|
TJ004309
|
CD73
|
Cancer
|
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
|
-
(5)
- HY-P992235
-
-
(5)
- HY-P991187
-
|
AGX-101 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991075
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991281
-
-
(5)
- HY-P99949
-
|
OMP-313M32
|
Inhibitory Antibodies
|
Cancer
|
|
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing .
|
-
(5)
- HY-P991604
-
|
YFC51.1; LDP-01
|
Integrin
|
Inflammation/Immunology
|
|
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
|
-
(5)
- HY-P991150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
-
(5)
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
|
-
(5)
- HY-P99295A
-
|
RG 7160 (FUT8-KO); RO 5083945 (FUT8-KO); Anti-EGFR Recombinant antibody (FUT8-KO)
|
EGFR
|
Cancer
|
|
Imgatuzumab (FUT8-KO) is a humanized monoclonal antibody against EGFR expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Imgatuzumab is an immunomodulator. Imgatuzumab may be used in cancer research.
|
-
(5)
- HY-P991723
-
|
CX-2051 antibody
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer .
|
-
(5)
- HY-P99285
-
|
hBU 12
|
ADC Antibody
CD19
|
Cancer
|
|
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
|
-
(5)
- HY-P99515
-
|
GR 1501
|
Interleukin Related
|
Inflammation/Immunology
|
|
Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade. Xeligekimab can be used for the research of inflammatory disease, such as radiographic axial spondyloarthritis .
|
-
(5)
- HY-P991265
-
|
|
Interleukin Related
|
Cancer
|
|
OSE-703 is a humanized monoclonal antibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases .
|
-
(5)
- HY-P991135
-
|
RO-7502175; RG-6411
|
CCR
|
Cancer
|
|
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
|
-
(5)
- HY-P99365
-
|
ALXN1210
|
Complement System
|
Metabolic Disease
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
-
(5)
- HY-P991711
-
|
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Povovetug is a humanized IgG1κ chimeric monoclonal antibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research .
|
-
(5)
- HY-P992355
-
|
GB7004-09hu15
|
Claudin
|
Cancer
|
|
GB7004-09 (GB7004-09hu15) is a humanized monoclonal antibody against CLDN18.2. GB7004-09 can be used in cancer research .
|
-
(5)
- HY-P991586
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
KB002 is a humanized monoclonal antibody inhibitor targeting GM-CSF. KB002 has significant immune activity and can be used for asthma, rheumatoid arthritis and chronic Idiopathic thrombocytopenia purpura (ITP) research .
|
-
(5)
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
-
(5)
- HY-P991650
-
|
|
PSMA
|
Cancer
|
|
MDX1201 is a humanized monoclonal antibody targeting PSMA1/7. MDX1201 conjugated with a fluorescent dye AlexaTM488 can be used as a probe for near-infrared fluorescence imaging (NIRF) imaging of prostate cancer .
|
-
(5)
- HY-P991195
-
|
SIM1811-03
|
TNF Receptor
|
Cancer
|
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
(5)
- HY-P99893
-
|
AMG-570
|
CD28
TNF Receptor
|
Inflammation/Immunology
|
|
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Rozibafusp alfa can be used for the research of systemic lupus erythematosus and other autoimmune diseases .
|
-
(5)
- HY-P991184
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody that targets LY6G6D. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P991145
-
|
|
SLC39 (Zinc Transporter)
|
Cancer
|
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
-
(5)
- HY-P9944
-
|
MEDI 493
|
RSV
|
Infection
Inflammation/Immunology
Cancer
|
|
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
|
-
(5)
- HY-P991688
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gimvekibart is a humanized IgG4κ monoclonal antibody inhibitor targeting IL-4Ra/CD124. Gimvekibart can be used for inflammatory diseases like idiopathic pulmonary fibrosis (IPF) research .
|
-
(5)
- HY-P99185
-
|
AAB-001
|
Amyloid-β
|
Neurological Disease
|
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
|
-
(5)
- HY-P991266
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .
|
-
(5)
- HY-P992123
-
|
AZD-5148
|
Bacterial
|
Infection
|
|
Ombetoxabart is a humanized IgG1-κ monoclonal antibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection .
|
-
(5)
- HY-P991690
-
|
|
RSV
|
Infection
|
|
Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
|
-
(5)
- HY-P991717
-
|
AZD-8630
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sunakiment is a humanized IgG1λ monoclonal antibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .
|
-
(5)
- HY-P991614
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
|
-
(5)
- HY-P990072
-
|
LZM-009
|
PD-1/PD-L1
|
Cancer
|
|
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
|
-
(5)
- HY-145627
-
|
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
|
-
(5)
- HY-P99015
-
|
|
TNF Receptor
|
Cancer
|
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
|
-
(5)
- HY-P99013
-
|
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
-
(5)
- HY-P991554
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
|
-
(5)
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
|
-
(5)
- HY-P991167
-
|
|
Bacterial
|
Infection
|
|
Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
|
-
(5)
- HY-P99439
-
|
IMA-638
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
|
-
(5)
- HY-P991608
-
|
7F11C7
|
Mucin
|
Cancer
|
|
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
|
-
(5)
- HY-P991635
-
|
|
TNF Receptor
|
Cancer
|
|
PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
|
-
(5)
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
-
(5)
- HY-P991258
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
|
-
(5)
- HY-P990070
-
|
BION-1301
|
TNF Receptor
|
|
|
Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonal antibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .
|
-
(5)
- HY-P991892
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 is a humanized anti-CD4 monoclonal IgG1 antibody. IT1208 depletes CD4 + T cells with a manageable safety profile in vivo. IT1208 can be used for colon cancer research .
|
-
(5)
- HY-P991041
-
|
Anti-SEZ6 antibody (SC17); ABBV-011 antibody; ABBV-706 antibody
|
ADC Antibody
|
Cancer
|
|
Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99471
-
|
UCB 0107
|
Tau Protein
|
Neurological Disease
|
|
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease .
|
-
(5)
- HY-P991556
-
|
|
TNF Receptor
|
Cancer
|
|
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
|
-
(5)
- HY-P9953
-
|
Certolizumab; CDP870
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
|
-
(5)
- HY-P99513
-
|
CTB011
|
RABV
|
Infection
|
|
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
|
-
(5)
- HY-P992131
-
|
|
Mucin
|
Cancer
|
|
Sacomitatug is a humanized IgG1-κ monoclonal antibody targeting mucin 1 (MUC1). Sacomitatug exerts anti-tumor effects by blocking MUC1-mediated tumor proliferation signals and activating immune effectors .
|
-
(5)
- HY-P991285
-
-
(5)
- HY-P991659
-
|
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
SCH708980 is a humanized monoclonal antibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research .
|
-
(5)
- HY-P99904
-
|
MEDI-507; TCD601
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
|
-
(5)
- HY-P991652
-
|
RG-7594
|
Integrin
|
Cancer
|
|
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .
|
-
(5)
- HY-P991130
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
|
-
(5)
- HY-P9975
-
|
TGN1412; TAB08
|
CD28
|
Inflammation/Immunology
|
|
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
|
-
(5)
- HY-P991183
-
|
|
CD28
CD38
CD3
|
Cancer
|
|
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells .
|
-
(5)
- HY-P991619
-
|
TF8-5G9
|
Transmembrane Glycoprotein
|
Cancer
|
|
CNTO-860 is a humanized anti-tissue factor monoclonal antibody. CNTO-860 can improve tumor control when combined with Paclitaxel (HY-B0015) in colon cancer model and significantly increase tumor-free survival .
|
-
(5)
- HY-P991082
-
|
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99369
-
|
IPH 4102; Anti-KIR3DL2/CD158k Reference antibody (lacutamab)
|
Inhibitory Antibodies
|
Cancer
|
|
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .
|
-
(5)
- HY-P991507
-
|
Demupitamab
|
EGFR
|
Cancer
|
|
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
|
-
(5)
- HY-P9968
-
|
h-R3
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
(5)
- HY-P99956
-
|
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
|
-
(5)
- HY-P9990
-
-
(5)
- HY-P991415
-
|
AM712
|
VEGFR
Tie
|
Others
|
|
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
-
(5)
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
|
-
(5)
- HY-P99540
-
|
PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
|
CTLA-4
|
Cancer
|
|
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991153
-
|
|
Virus Protease
|
Infection
|
|
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
|
-
(5)
- HY-P99028
-
|
TMB-355; TNX-355
|
HIV
|
Infection
|
|
Ibalizumab (TMB-355) is a humanized anti-CD4 IgG4 monoclonal antibody. Ibalizumab prevents HIV cell entry by binding to CD4 receptor. Ibalizumab can be used for the research of infection, such as HIV-1 infection .
|
-
(5)
- HY-P99858
-
|
AB154
|
Transmembrane Glycoprotein
|
Cancer
|
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
|
-
(5)
- HY-P991222
-
|
|
Phosphatase
|
Cardiovascular Disease
|
|
AMG-529 is a humanized monoclonal antibody against ASGR1 that binds to ASGR1, blocks ligand binding, and causes a dose-dependent increase in ALP (a biomarker of ASGR1 inhibition). AMG-529 can be used for the research of cardiovascular diseases .
|
-
(5)
- HY-P991589
-
|
NOV-1105
|
c-Met/HGFR
|
Cancer
|
|
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
|
-
(5)
- HY-P991612
-
|
Sym024
|
CD73
|
Inflammation/Immunology
Cancer
|
|
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
|
-
(5)
- HY-P991123
-
|
ALD1910; LU AG-09222
|
Adenylate Cyclase
|
Inflammation/Immunology
|
|
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
|
-
(5)
- HY-P990026A
-
-
(5)
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
-
(5)
- HY-P99886
-
|
h5G1. 1-SC
|
Complement System
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
|
-
(5)
- HY-P99172
-
|
|
CD47
Interleukin Related
|
Cancer
|
|
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
|
-
(5)
- HY-P992463
-
|
|
Ser/Thr Protease
|
Endocrinology
|
|
SHR-2010 is a fully humanized monoclonal antibody targeting MASP-2. SHR-2010 selectively inhibits lectin pathway activation without affecting classical or alternative complement pathways. SHR-2010 can be used for the research of IgA nephropathy .
|
-
(5)
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
(5)
- HY-P99112
-
|
RG-6168; SA-237
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
|
-
(5)
- HY-P991261
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
|
-
(5)
- HY-P990896
-
|
|
ADC Antibody
|
Cancer
|
|
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
|
-
(5)
- HY-P991174
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991638
-
|
|
TNF Receptor
|
Cancer
|
|
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP). XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research .
|
-
(5)
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991186
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model .
|
-
(5)
- HY-P99213
-
|
GSK1223249
|
Inhibitory Antibodies
|
Neurological Disease
Inflammation/Immunology
|
|
Ozanezumab (GSK1223249) is a humanized, Fc-inactivated monoclonal antibody that targets the nervous system protein Nogo-A. Ozanezumab promotes neurite outgrowth and axonal regeneration by neutralizing Nogo-A signaling. Ozanezumab is used for research on neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis [1] .
|
-
(5)
- HY-P991251
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
|
-
(5)
- HY-P992125
-
|
HFB-200603
|
CD28
|
Cancer
|
|
Radanstobart (HFB-200603) is a humanized monoclonal antibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991689
-
|
|
VEGFR
|
Cancer
|
|
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research .
|
-
(5)
- HY-P99327
-
|
BT-061
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
|
-
(5)
- HY-P990764B
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991647
-
|
|
CXCR
|
Cancer
|
|
ALX-0651 is a biparatopic humanized monoclonal antibody inhibitor targeting CXCR4. ALX-0651 inhibits hematopoietic stem cell trafficking, tumor progression and metastasis. ALX-0651 can be used for non-Hodgkin’s lymphoma and multiple myeloma research .
|
-
(5)
- HY-P99224
-
|
IMMU-106; hA20
|
Integrin
|
Cancer
|
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
|
-
(5)
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
(5)
- HY-P9968A
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
(5)
- HY-P992412
-
|
|
Claudin
|
Cancer
|
|
MIL93 is a humanized defucosylated IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
(5)
- HY-P99368
-
|
MCS110
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
|
-
(5)
- HY-P990007
-
|
PRA023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .
|
-
(5)
- HY-P99216
-
|
PF-04360365; RN 1219
|
Amyloid-β
|
Neurological Disease
|
|
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .
|
-
(5)
- HY-P9907A
-
|
Anti-Human HER2, Humanized antibody (anti-HER2)
|
ADC Antibody
EGFR
|
Cancer
|
|
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
(5)
- HY-P99317
-
|
LY-2062430
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .
|
-
(5)
- HY-P99215
-
|
Anti-EGFL7; RG 7414
|
VEGFR
|
Cancer
|
|
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
|
-
(5)
- HY-P992167
-
|
|
Claudin
|
Cancer
|
|
AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .
|
-
(5)
- HY-P99659
-
|
ANB 019
|
Interleukin Related
|
Inflammation/Immunology
|
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
|
-
(5)
- HY-P991993
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
AB054 is a humanized monoclonal antibody targeting factor XII (FXII). AB054 inhibits FXII activation and FXIIa activity through specific binding to the catalytic domain of FXII, and exerts antithrombotic effects in a concentration-dependent manner. AB054 can be used in studies related to thrombosis .
|
-
(5)
- HY-P990609
-
|
|
EGFR
|
Inflammation/Immunology
|
|
KHK-2866 is a recombinant humanized monoclonal antibody targeting heparin-binding epidermal growth factor-like growth factor (HB-EGF). The predicted molecular weight (MW) of KHK-2866 is 147.68 kDa. KHK-2866 can be used for tumor research .
|
-
(5)
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
(5)
- HY-P991282
-
|
|
Interleukin Related
|
Cancer
|
|
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
|
-
(5)
- HY-P991113
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
|
-
(5)
- HY-P991593
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
|
-
(5)
- HY-P99727
-
|
CTB012
|
RABV
|
Infection
|
|
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
|
-
(5)
- HY-P990022
-
|
DS-6016A
|
TGF-β Receptor
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .
|
-
(5)
- HY-P990051
-
|
AOC-1001 antibody; AOC-1044 antibody
|
Transferrin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Delpacibart is a humanized IgG1κ monoclonal antibody targeting the transferrin receptor TFRC. Delpacibart can be conjugated with the phosphorodiamidate morpholino oligonucleotide (PMO) Zotadirsen (HY-177972), which targets exon 44 of the dystrophin gene, to synthesize the antibody-oligonucleotide conjugate (AOC) Delpacibart zotadirsen (HY-177564). Delpacibart is suitable for use in Duchenne muscular dystrophy (DMD44) research .
|
-
(5)
- HY-P99101
-
|
AEX-4089; MGC026 antibody
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
|
-
(5)
- HY-P99964
-
|
AGS15C; Ha15-10ac12; Ha15-10ac12.1
|
Inhibitory Antibodies
|
Cancer
|
|
Sirtratumab (AGS15C; Ha15-10ac12; Ha15-10ac12.1) is a SLITRK6-specific humanized IgG2 monoclonal antibody, and serves as the parental antibody of the ADC ASG-15ME (HY-P99595). Sirtratumab is applicable for cancer research .
|
-
(5)
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
-
(5)
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
-
(5)
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
(5)
- HY-P991237
-
|
HMBD-001
|
EGFR
|
Cancer
|
|
Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
|
-
(5)
- HY-P991555
-
|
|
TNF Receptor
Apoptosis
|
Cancer
|
|
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
|
-
(5)
- HY-P991144
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
|
-
(5)
- HY-P991129
-
|
QX-002N
|
Interleukin Related
|
Inflammation/Immunology
|
|
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
(5)
- HY-P99412
-
|
OSE-127
|
Interleukin Related
|
Cancer
|
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
|
-
(5)
- HY-P99162
-
|
CIM331; CD14152
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
-
(5)
- HY-P99050
-
|
BIVV009; IPN-009; TNT009
|
Complement System
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
|
-
(5)
- HY-P991040
-
|
Gamsitabart; M3554 antibody
|
Inhibitory Antibodies
|
Cancer
|
|
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
|
-
(5)
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
(5)
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
(5)
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
|
-
(5)
- HY-P991657
-
|
|
Complement System
|
Cardiovascular Disease
|
|
MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury .
|
-
(5)
- HY-P992436
-
|
|
Integrin
|
Neurological Disease
|
|
PAS-003 is a humanized monoclonal antibody targerting α5β1 integrin. PAS-003 modulates immune cell migration, immune cell adhesion, improves behavior, and improves survival in ALS mouse models. PAS-003 can be used for the research of amyotrophic lateral sclerosis .
|
-
(5)
- HY-P9951A
-
|
RG-6321 (anti-VEGF)
|
VEGFR
|
Cardiovascular Disease
|
|
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
|
-
(5)
- HY-P99791
-
|
SYNT001; ALXN1830
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity .
|
-
(5)
- HY-P99177
-
|
|
Inhibitory Antibodies
|
Cardiovascular Disease
Infection
|
|
Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure .
|
-
(5)
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
-
(5)
- HY-P992132
-
|
STAR-0310
|
TNF Receptor
|
Inflammation/Immunology
|
|
Solaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4/OX40L. Solaprubart regulates immune homeostasis by blocking the OX40L-OX40 signaling pathway and can be used for the research of autoimmune diseases such as atopic dermatitis .
|
-
(5)
- HY-P992080
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is a humanized monoclonal antibody targeting H7N9. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) induces antibody-dependent cellular cytotoxicity (ADCC) against cells expressing H7N9 HA. Anti-Flu A (H7N9) HA/Hemagglutinin Antibody (m826) is applicable to studies related to H7N9 avian influenza virus infection .
|
-
(5)
- HY-P99901
-
|
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
|
-
(5)
- HY-P991250
-
|
|
Integrin
|
Cancer
|
|
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
|
-
(5)
- HY-P990902A
-
|
BMS-986012 (FUT8-KO)
|
Inhibitory Antibodies
|
Cancer
|
|
Atigotatug (FUT8-KO) is an anti-fuc-GM1 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out, and fucose deficiency enhances the ADCC effect of the antibody. Atigotatug (HY-P990902) is a Fucosyl ganglioside GM1 (fuc-GM1)-targeting IgG1κ type humanized antibody. Atigotatug can induce immune-mediated tumor cell death, such as small cell lung cancer .
|
-
(5)
- HY-P990025
-
|
ARGX-117
|
Complement System
|
Inflammation/Immunology
|
|
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
|
-
(5)
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
(5)
- HY-P991708
-
|
REGN-4336
|
PSMA
CD3
|
Cancer
|
|
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
|
-
(5)
- HY-P9950
-
|
Olizumab; rhuMab-E25; IGE25; RG-3648
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
|
-
(5)
- HY-P991066
-
|
ARGX-119
|
nAChR
|
Neurological Disease
|
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
(5)
- HY-P991283
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
|
-
(5)
- HY-P991665
-
|
OBT357NF; OBT357
|
Transmembrane Glycoprotein
|
Cancer
|
|
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
|
-
(5)
- HY-P992508
-
|
SX001
|
Claudin
|
Cancer
|
|
SPX-101 (SX001) is a humanized monoclonal antibody targeting CLDN18.2. CLDN18.2 is only transiently expressed in the differentiated epithelial cells of the gastric mucosa and is hardly found in healthy tissues, thus having an extremely wide therapeutic window. SPX-101 can be used for the study of solid tumors.
|
-
(5)
- HY-P99345
-
|
TSR-042; ANB-011; WBP-285
|
PD-1/PD-L1
|
Cancer
|
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
-
(5)
- HY-P991636
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
|
-
(5)
- HY-P991052
-
|
|
TNF Receptor
|
Cancer
|
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P990937
-
|
PF-04236921; TOUR-006
|
Interleukin Related
|
Inflammation/Immunology
|
|
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
|
-
(5)
- HY-P99037
-
|
M281
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
|
-
(5)
- HY-P99233
-
|
HuMax-TAC
|
ADC Antibody
Transmembrane Glycoprotein
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991588
-
|
AC101
|
EGFR
Apoptosis
|
Cancer
|
|
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
|
-
(5)
- HY-P99961
-
|
JS004; Icatolimab
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer .
|
-
(5)
- HY-P99493
-
|
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
(5)
- HY-P99252
-
|
Anti-Human CD6 Recombinant antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
-
(5)
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant antibody
|
CD28
Apoptosis
|
Cancer
|
|
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
|
-
(5)
- HY-P992376
-
|
NBE-002 antibody
|
ROR
|
Cancer
|
|
huXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonal antibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis) .
|
-
(5)
- HY-P9918
-
|
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
-
(5)
- HY-P991363
-
|
|
Myosin
STAT
|
Inflammation/Immunology
|
|
AX-202 is a humanized IgG4 monoclonal antibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .
|
-
(5)
- HY-P99239
-
|
HUJ-591; TLX591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
-
(5)
- HY-P990071
-
|
LY-3016859
|
EGFR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP) .
|
-
(5)
- HY-P991173
-
|
|
Notch
|
Cancer
|
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991248
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) .
|
-
(5)
- HY-P991178
-
|
|
TNF Receptor
|
Cancer
|
|
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
|
-
(5)
- HY-P991569
-
|
|
Wnt
|
Metabolic Disease
Endocrinology
|
|
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
|
-
(5)
- HY-P99256
-
|
SCH 900222; MK 3222; Anti-Human IL23 Recombinant antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
|
-
(5)
- HY-P991151
-
|
|
PD-1/PD-L1
TNF Receptor
|
Cancer
|
|
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
|
-
(5)
- HY-P991574
-
|
REG-101
|
ATGL
|
Cardiovascular Disease
|
|
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
|
-
(5)
- HY-P9978
-
|
JS-001
|
PD-1/PD-L1
|
Cancer
|
|
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
|
-
(5)
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
|
-
(5)
- HY-P9948
-
|
Campath-IH
|
Apoptosis
|
Cancer
|
|
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
|
-
(5)
- HY-P990914
-
|
GS-1811; JTX-1811
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Denikitug (GS-1811; JTX-1811) is a humanized monoclonal antibody against CCR8 receptor with a KD of 16.8 pM. Denikitug specifically binds to human CCR8, inhibits CCL1-induced downstream CCR8 signaling. Denikitug selectively depletes cells expressing CCR8 via antibody-dependent cellular cytotoxicity (ADCC). Denikitug promotes anti-tumor immunity and can be used for the research of cancer and immunology .
|
-
(5)
- HY-P99866
-
|
MEHD-7945A; RG 7597
|
EGFR
Akt
p38 MAPK
Apoptosis
|
Cancer
|
|
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
|
-
(5)
- HY-P9983
-
|
SGN-33; HuM-195; GLK-33 antibody
|
Transmembrane Glycoprotein
Radionuclide-Drug Conjugates (RDCs)
|
Inflammation/Immunology
|
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
|
-
(5)
- HY-P991995
-
|
OMTX705 antibody
|
ADC Antibody
FAP
|
Cancer
|
|
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .
|
-
(5)
- HY-P99051
-
|
BAY 1834942
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
|
-
(5)
- HY-P990006
-
|
TEV-48574; SAR-447189; TEV-574
|
TNF Receptor
|
Inflammation/Immunology
|
|
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
-
(5)
- HY-P991957
-
|
|
Prion Protein
|
Neurological Disease
|
|
PRN100 is a fully humanized monoclonal antibody against cellular prion protein (PrPᶜ), belonging to the IgG4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.
|
-
(5)
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .
|
-
(5)
- HY-P991244
-
|
|
EGFR
|
Cancer
|
|
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
|
-
(5)
- HY-P991246
-
|
|
Virus Protease
HIV
|
Infection
|
|
VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
|
-
(5)
- HY-P99525
-
|
R 84 (antibody); GNR-011
|
VEGFR
|
Cancer
|
|
Varisacumab (R 84; GNR-011) is a fully humanized IgG1 monoclonal antibody targeting VEGF. Varisacumab specifically blocks the interaction between VEGF and VEGFR2, but does not interfere with the interaction between VEGF and VEGFR1. Varisacumab achieves effective anti-tumor and anti-angiogenic effects and can be used in the research of non-small cell lung cancer and pancreatic cancer.
|
-
(5)
- HY-P991558
-
|
RG-7356
|
Transmembrane Glycoprotein
|
Cancer
|
|
RO-5429083 (RG-7356) is a humanized monoclonal antibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .
|
-
(5)
- HY-P990045
-
|
ALE.F02
|
Claudin
|
Endocrinology
|
|
Lixudebart (ALE.F02) is a humanized immunoglobulin G1-kappa, anti-CLDN1 monoclonal antibody. Lixudebart disrupts CLDN1 interactions with CD44 and MMP14, reduces renal macrophage infiltration, epithelial activation, and urinary albumin-to-creatinine ratio, and attenuates glomerulosclerosis. Lixudebart can be used for the research of focal segmental glomerulosclerosis .
|
-
(5)
- HY-P991653
-
|
|
CCR
HIV
|
Infection
|
|
HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research .
|
-
(5)
- HY-P991729
-
|
APG-777
|
Interleukin Related
|
Inflammation/Immunology
|
|
Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zumilokibart can be used for the research of atopic dermatitis (AD) .
|
-
(5)
- HY-P99304
-
|
Anti-Human ERBB3 Recombinant antibody
|
EGFR
PI3K
Akt
p38 MAPK
|
Cancer
|
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .
|
-
(5)
- HY-P992176
-
|
|
CD47
|
Cancer
|
|
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a Kd value of 11.0 × 10 -9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma .
|
-
(5)
- HY-P99045
-
|
HRS7; hRS7
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
(5)
- HY-P992346
-
|
|
CD47
|
Cancer
|
|
DS-1103a is a humanized IgG4 monoclonal antibody targeting SIRPa/CD172a. DS-1103a inhibits the interaction between SIRPα and CD47. DS-1103a enhances antibody-dependent cellular phagocytosis of cancer cells. DS-1103a can be used for the research of solid tumors. The recommended isotype control is: Human IgG4 (S228P) kappa, (HY-P99003) .
|
-
(5)
- HY-P990730
-
|
ARB202
|
CD3
Cadherin
|
Cancer
|
|
Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers .
|
-
(5)
- HY-P99229
-
|
XMT-1535; Upinitatug
|
ADC Antibody
|
Cancer
|
|
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P9907
-
Trastuzumab
Maximum Cited Publications
55 Publications Verification
Anti-Human HER2, Humanized antibody
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
ADC Antibody
|
Cancer
|
|
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
|
-
(5)
- HY-P990591
-
|
Aletekitug
|
Interleukin Related
|
Inflammation/Immunology
|
|
GSK-1070806 (Aletekitug) is a humanized IgG1/κ monoclonal antibody targeting IL-18. GSK-1070806 neutralizes IL-18 activity.GSK-1070806 can be used for the research of inflammation. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99391
-
|
ABT-700; ABBV-400 antibody
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
(5)
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
-
(5)
- HY-P991272
-
|
PF-05230900
|
Interleukin Related
|
Inflammation/Immunology
|
|
ATR-107 (PF-05230900) is a humanized monoclonal antibody inhibitor that targets the interleukin-21 receptor (IL-21R). The Ka value of ATR-107 is 2-4 nM in cynomolgus monkeys, 16 nM in mice, and 71 nM in rats. ATR-107 can be used in research related to systemic lupus erythematosus and air pouch inflammation .
|
-
(5)
- HY-P991655
-
|
|
IFNAR
HIV
|
Infection
Inflammation/Immunology
|
|
AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
|
-
(5)
- HY-P9949
-
|
Sch 55700; CDP-835; JES1-39D10
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
-
(5)
- HY-P991240
-
|
KTN-3379
|
EGFR
|
Cancer
|
|
CDX-3379 is a humanized monoclonal antibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
|
-
(5)
- HY-P99382
-
|
JTX 2011; 37A10
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response .
|
-
(5)
- HY-P991651
-
|
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
|
-
(5)
- HY-P9929
-
|
BLA761046; MBL-CDB1; MDX-1388
|
Bacterial
|
Infection
|
|
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
|
-
(5)
- HY-P990753
-
|
CAN-106
|
Complement System
|
Inflammation/Immunology
|
|
Omoprubart is an anti-C5 complement recombinant humanized monoclonal antibody. Omolubat can prevent C5 from cleaving into C5a and C5b, thereby inhibiting the formation and activation of the C5b-dependent membrane attack complex (MAC) on the surface of susceptible cells, leading to cell lysis (destruction). Omoprubart can be used for the study of paroxysmal nocturnal hemoglobinuria (PNH).
|
-
(5)
- HY-P99731
-
|
hLL1; MEDI-115
|
CD74
|
Cancer
|
|
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
|
-
(5)
- HY-P991620
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
|
-
(5)
- HY-P992399
-
|
|
TNF Receptor
NF-κB
|
Cancer
|
|
LBL-019 is a humanized IgG1 monoclonal antibody targeting TNFR2. LBL-019 costimulates TNFR2 and activates the NF-κB signaling pathway in an Fc crosslinking-dependent manner. LBL-019 can be used for the research of advanced malignant tumors, including hepatocellular carcinoma and melanoma. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P99414
-
|
AMG 557
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
|
|
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
(5)
- HY-P991146
-
|
LZM-012; XKH004
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
(5)
- HY-P99492
-
|
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
(5)
- HY-P991534
-
|
|
Amyloid-β
|
Neurological Disease
|
|
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
|
-
(5)
- HY-P99045A
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
|
-
(5)
- HY-P99970
-
|
|
ADC Antibody
Sodium Phosphate Cotransporter
|
Cancer
|
|
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991892A
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
|
-
(5)
- HY-P991610
-
|
Sym025
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
|
-
(5)
- HY-P991542
-
|
|
CD19
|
Cancer
|
|
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
|
-
(5)
- HY-P991267
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
CAN10 is is a humanized monoclonal antibody inhibitor targeting interleukin 1RAP (IL1RAP). CAN10 blocks IL-1, IL-33, and IL-36 signalling by targeting IL1RAP, preventing downstream proinflammatory and profibrotic responses. CAN10 reduces dermal and pulmonary fibrosis. CAN10 can be used for the research of immune system diseases, such as systemic sclerosis .
|
-
(5)
- HY-P99581
-
|
OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
|
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma .
|
-
(5)
- HY-P99009
-
|
RVT-1401; HBM9161; IMVT-1401
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
|
-
(5)
- HY-P992461
-
|
|
LAG-3
|
Cancer
|
|
SHR-1802 is a humanized anti-LAG-3 monoclonal antibody.SHR-1802 specifically binds to LAG-3 and inhibits its binding to major histocompatibility complex class II (MHC-II), fibrinogen-like protein 1 (FGL1), galectin-3, and liver sinusoidal endothelial cell lectin.SHR-1802 can be used for the research of advanced solid tumors .
|
-
(5)
- HY-P99391A
-
|
ABT-700 (powder)
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
|
-
(5)
- HY-P990061
-
|
JTX 8064
|
LILRB
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
|
-
(5)
- HY-P99199
-
|
NI-0401
|
CD3
|
Inflammation/Immunology
|
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
-
(5)
- HY-P992113
-
|
|
β-catenin
Wnt
|
Metabolic Disease
|
|
Evabosmig is a multispecific antibody targeting SOST, DKK-1 and ALB. Evabosmig can be used for the study of osteoporosis .
|
-
(5)
- HY-P992447
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .
|
-
(5)
- HY-P991294
-
|
|
ADC Antibody
|
Cancer
|
|
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
|
-
(5)
- HY-P991561
-
|
|
CD47
|
Cancer
|
|
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
|
-
(5)
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
-
(5)
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
-
(5)
- HY-P9924
-
|
LY2439821
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
|
-
(5)
- HY-P990667
-
|
BG00011
|
Integrin
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
STX-100 (BG00011) is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .
|
-
(5)
- HY-P991654
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
|
-
(5)
- HY-P99682
-
|
hLIV22
|
ADC Antibody
|
Cancer
|
|
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
|
-
(5)
- HY-P9972
-
|
PDR001
|
PD-1/PD-L1
IFNAR
|
Cancer
|
|
Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
|
-
(5)
- HY-P991220
-
|
|
TREM receptor
|
Neurological Disease
|
|
AL002 is a humanized monoclonal IgG1 antibody and a blood-brain barrier-permeable TREM2 modulator. AL002 binds to TREM2 on the surface of microglia, promotes TREM2 clustering and the formation of the TREM2-DAP12 complex, activates the TREM2 signaling pathway and PI3K cascade, and induces TREM2 internalization and degradation. AL002 is applicable to research related to Alzheimer's disease .
|
-
(5)
- HY-P991609
-
|
|
MMP
|
Cancer
|
|
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
|
-
(5)
- HY-P991572
-
|
|
EGFR
|
Cancer
|
|
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
|
-
(5)
- HY-P991867
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991201
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P991585
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .
|
-
(5)
- HY-P99242
-
|
|
CD276/B7-H3
|
Cancer
|
|
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
|
-
(5)
- HY-P991633
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
|
-
(5)
- HY-P991720
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
|
-
(5)
- HY-P991646
-
|
heMab
|
Transmembrane Glycoprotein
|
Cancer
|
|
ING-1 (heMab) is a high-affinity humanized monoclonal antibody against epithelial cell adhesion molecule (Ep-CAM). ING-1 is a transmembrane glycoprotein mediating Ca 2+. ING-1 binds to Ep-CAM on tumor cells and exhibits potent in vitro activity, targeting and inhibiting tumor growth and metastasis in mouse cancer models. ING-1 is useful in the research of breast, colorectal, and lung cancers, among other cancers .
|
-
(5)
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
-
(5)
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
-
(5)
- HY-P99263
-
|
Anti-Human selectin P Recombinant antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
-
(5)
- HY-P991611
-
|
|
iGluR
|
Inflammation/Immunology
|
|
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
|
-
(5)
- HY-P991960
-
|
|
CTLA-4
Interleukin Related
|
Cancer
|
|
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
|
-
(5)
- HY-P991592
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ)-transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research .
|
-
(5)
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
-
(5)
- HY-P99754
-
|
BCD-085
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
- HY-P99325
-
|
IDEC-131; Anti-Human CD40 ligand Recombinant antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
|
-
(5)
- HY-P991582
-
|
|
Fc Receptor (FcR)
|
Cancer
|
|
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
|
-
(5)
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P99828
-
|
PF-06523435; hu24
|
ADC Antibody
RET
PERK
ROR
|
Cancer
|
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer .
|
-
(5)
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
(5)
- HY-P99613
-
|
MK-4280; Mavezelimab
|
LAG-3
|
Cancer
|
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma . For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
(5)
- HY-P991570
-
|
AD5-10; oba-01 antibody
|
TNF Receptor
Apoptosis
Caspase
Atg8/LC3
Akt
Beclin1
JNK
|
Cancer
|
|
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models .
|
-
(5)
- HY-P992344
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .
|
-
(5)
- HY-P99712
-
|
hz208F2-4
|
IGF-1R
Apoptosis
ADC Antibody
|
Cancer
|
|
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye
diseases .
|
-
(5)
- HY-P992367
-
|
|
TROP2
|
Cancer
|
|
hIMB1636 is a humanized monoclonal antibody targeting Trop2. By binding to the conformational Trop2 epitope, hIMB1636 regulates related signaling pathways, triggers lysosomal endocytosis, and further induces apoptosis, cell cycle arrest, and antibody-dependent cellular cytotoxicity. hIMB1636 effectively inhibits tumor cell proliferation, migration and in vivo tumor growth, and also exerts bystander killing effect and mediates long-term retention. hIMB1636 can be conjugated with NOTA/DOTA for radiolabeling to enable immuno-PET imaging, or prepared as hIMB1636-LDP-AE to significantly inhibit the growth of breast cancer and lung cancer xenografts .
|
-
(5)
- HY-P9980
-
|
GSK2857914
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
|
-
(5)
- HY-P991674
-
|
BJT-778
|
HBV
|
Infection
Inflammation/Immunology
|
|
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with Kd values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC50 values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .
|
-
(5)
- HY-P991480
-
|
|
Transmembrane Glycoprotein
Tau Protein
Amyloid-β
|
Neurological Disease
Cancer
|
|
ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease .
|
-
(5)
- HY-P991671
-
|
JNJ-80948543
|
CD3
CD20
Transmembrane Glycoprotein
|
Cancer
|
|
Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
|
-
(5)
- HY-P99809
-
|
MK-1308
|
CTLA-4
|
Cancer
|
|
Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
|
-
(5)
- HY-P991567
-
|
VX5/5261
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
|
-
(5)
- HY-P992023
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
APX002 is an anti-IL-1β humanized monoclonal antibody that binds to IL-1β with an affinity of 1.99×10 ?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis .
|
-
(5)
- HY-P991515
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
|
-
(5)
- HY-P99014
-
|
ARGX-110
|
Fc Receptor (FcR)
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
|
-
(5)
- HY-P99176
-
ATG-031
4 Publications Verification
|
Inhibitory Antibodies
|
Cancer
|
|
ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P991551
-
|
|
Dipeptidyl Peptidase
p38 MAPK
ERK
|
Infection
Cancer
|
|
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS .
|
-
(5)
- HY-P99404
-
|
E6011
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .
|
-
(5)
- HY-P991599
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P991217
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
|
-
(5)
- HY-P991956
-
|
|
Transmembrane Glycoprotein
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
ABB071 is a humanized anti-CD180 monoclonal antibody. ABB071 can down-regulate the highly expressed TLR7 and IRF5 genes in systemic lupus erythematosus and induce the expression of PNPT1 and DNASE1L3 genes. ABB071 can inhibit the expression of genes related to the type I interferon pathway as well as interferon-stimulated genes (ISGs). ABB071 has anti-inflammatory activity and can reduce the levels of inflammatory cytokines. ABB071 can be used for research on systemic lupus erythematosus and psoriasis .
|
-
(5)
- HY-P991565
-
|
|
c-Met/HGFR
|
Cancer
|
|
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
|
-
(5)
- HY-P99019
-
|
TEV-48125; LBR-101; PF-04427429; RN-307
|
CGRP Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .
|
-
(5)
- HY-P991598
-
|
MOR12743; MOR03207
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
|
-
(5)
- HY-P3371
-
|
DS-7300a; MABX-9001a; I-DXd
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
Apoptosis
|
Cancer
|
|
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
|
-
(5)
- HY-P991223
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Cancer
|
|
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
|
-
(5)
- HY-P99300
-
|
QGE 031; Anti-IGHE Recombinant antibody
|
Fc Receptor (FcR)
|
Inflammation/Immunology
|
|
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
|
-
(5)
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
(5)
- HY-P992388
-
|
|
LILRB
|
Cancer
|
|
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
|
-
(5)
- HY-P992381
-
|
|
Drug Derivative
|
Cancer
|
|
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
|
-
(5)
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
(5)
- HY-P991634
-
|
|
CD73
TNF Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
|
-
(5)
- HY-P992372
-
|
|
Drug Derivative
Transmembrane Glycoprotein
|
Cancer
|
|
huAA98 is a humanized monoclonal antibody and also a CD146 inhibitor. huAA98 binds to human CD146, regulates its activity and inhibits cancer-related angiogenesis, as well as tube formation, motility, proliferation and migration of endothelial cells. huAA98 inhibits angiogenesis in the chick chorioallantoic membrane assay and reduces microvessel density in human tumor xenograft models. huAA98 shows immunoreactivity only to neovascular vessels within tumors and inhibits the growth of tumor xenograft models. huAA98 can be used in studies related to cancer-related angiogenesis, liver cancer, leiomyosarcoma and pancreatic cancer .
|
-
(5)
- HY-P991566
-
|
|
CTLA-4
|
Cancer
|
|
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
|
-
(5)
- HY-P991621
-
|
EOS-215
|
TREM receptor
|
Cancer
|
|
EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .
|
-
(5)
- HY-P992045
-
|
|
Interleukin Related
CXCR
|
Inflammation/Immunology
|
|
HZD37-5 is a humanized monoclonal antibody specifically recognizing N78 loci of IL-17A. HZD37-5 binds to human and rhesus monkeys, blocks IL-17 induced signal transduction and the release of IL-6, IL-8, CXCL-1 and GM-GSF. HZD37-5 significantly inhibited human IL-17A induced-keratinocyte chemoattractant secretion. HZD37-5 can be used for the research of autoimmune diseases including psoriasis and psoriatic arthritis .
|
-
(5)
- HY-P991656
-
|
|
CXCR
Apoptosis
p38 MAPK
Akt
|
Cancer
|
|
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .
|
-
(5)
- HY-P991155
-
|
JNJ-79635322; JNJ-5322
|
CD3
TNF Receptor
|
Cancer
|
|
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
|
-
(5)
- HY-P991198
-
|
|
Tim3
|
Cancer
|
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
-
(5)
- HY-P991595
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
- HY-P992172
-
|
|
Tau Protein
|
Neurological Disease
|
|
ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies .
|
-
(5)
- HY-P991444
-
|
|
NTPDase
ATP Synthase
|
Inflammation/Immunology
Cancer
|
|
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors .
|
-
(5)
- HY-P991584
-
|
|
FGFR
|
Cancer
|
|
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
|
-
(5)
- HY-108738
-
|
Ro 24-7375
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
|
-
(5)
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
- HY-P992380
-
|
|
PD-1/PD-L1
|
Neurological Disease
|
|
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .
|
-
(5)
- HY-P99157
-
|
|
CD276/B7-H3
|
Cancer
|
|
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
|
-
(5)
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Neurological Disease
|
|
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
|
-
(5)
- HY-P99395
-
|
JNJ 56022473; CSL 362
|
Interleukin Related
|
Cancer
|
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
|
-
(5)
- HY-P992340
-
|
|
Radionuclide-Drug Conjugates (RDCs)
TNF Receptor
|
Cancer
|
|
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .
|
-
(5)
- HY-P992382
-
|
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003 .
|
-
(5)
- HY-P990093
-
|
CM310
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .
|
-
(5)
- HY-P992356
-
|
|
Topoisomerase
|
Cancer
|
|
GENA-104A16 is a humanized monoclonal antibody targeting CNTN4, with multiple functions including immunostimulation, cytotoxicity and immunoregulation. By binding to CNTN4, GENA-104A16 blocks its interaction with APP, thereby restoring T cell function, inducing tumor cell death and regulating tumor-infiltrating immune cell populations. GENA-104A16 also exerts topoisomerase I inhibitory activity via the payload Exatecan (HY-13631). GENA-104A16 can be used in research related to colon cancer liver metastasis and other CNTN4-expressing solid tumors .
|
-
(5)
- HY-P991927
-
|
|
CD47
|
Cancer
|
|
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
|
-
(5)
- HY-P992434
-
|
|
PD-1/PD-L1
SHP1
Interleukin Related
|
Cancer
|
|
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .
|
-
(5)
- HY-P99488
-
|
JSP-191; AMG-191
|
c-Kit
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
|
-
(5)
- HY-P99048A
-
|
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
(5)
- HY-P99496
-
|
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
-
(5)
- HY-P991959
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
JMW-3B3 is a humanized IgG1λ monoclonal antibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.
|
-
(5)
- HY-P991193
-
|
|
TNF Receptor
|
Cancer
|
|
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a Ka of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 + T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .
|
-
(5)
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
|
-
(5)
- HY-108831A
-
|
AN100226; BG00002
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
|
-
(5)
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
